<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD with MathML3 v1.1 20151215//EN" "JATS-journalpublishing1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink"
         xmlns:mml="http://www.w3.org/1998/Math/MathML"
         xmlns:ali="http://www.niso.org/schemas/ali/1.0/"
         xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         dtd-version="1.1"
         xml:lang="sl"
         article-type="other">
   <front>
      <journal-meta>
         <journal-id journal-id-type="publisher-id">Zdrav Vestn</journal-id>
         <journal-id journal-id-type="nlm-ta">Zdrav Vestn</journal-id>
         <journal-id journal-id-type="doi">Zdrav Vestn</journal-id>
         <journal-title-group>
            <journal-title>Zdravniški vestnik</journal-title>
            <trans-title-group xml:lang="en">
               <trans-title>Slovenian Medical Journal</trans-title>
            </trans-title-group>
            <abbrev-journal-title>Zdrav Vestn</abbrev-journal-title>
         </journal-title-group>
         <issn publication-format="ppub" pub-type="ppub">1318-0347</issn>
         <issn publication-format="epub" pub-type="epub">1581-0224</issn>
         <issn-l>0350-0063</issn-l>
         <publisher>
            <publisher-name xml:lang="sl">Slovensko zdravniško društvo</publisher-name>
            <publisher-name xml:lang="en">Slovenian Medical Association</publisher-name>
            <publisher-loc xml:lang="sl">Ljubljana, Slovenia</publisher-loc>
         </publisher>
      </journal-meta>
      <article-meta>
         <article-id pub-id-type="doi">10.6016/ZdravVestn.2844</article-id>
         <article-id pub-id-type="publisher-id">2844</article-id>
         <article-categories>
            <subj-group subj-group-type="discipline" xml:lang="en">
               <subject>Medicine and health sciences</subject>
               <subj-group>
                  <subject>Metabolic and hormonal disorders</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="discipline" xml:lang="sl">
               <subject>Medicina/Zdravstvo</subject>
               <subj-group>
                  <subject>Metabolne in hormonske motnje</subject>
               </subj-group>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="en">
               <subject>Review article</subject>
            </subj-group>
            <subj-group subj-group-type="article-type" xml:lang="sl">
               <subject>Pregledni znanstveni članek</subject>
            </subj-group>
            <subj-group subj-group-type="heading" xml:lang="sl">
               <subject>Metabolne in hormonske motnje</subject>
            </subj-group>
         </article-categories>
         <title-group>
            <article-title xml:lang="sl">Peritonitis pri bolnikih na peritonealni dializi</article-title>
            <trans-title-group>
               <trans-title xml:lang="en">Peritoneal dialysis-associated peritonitis</trans-title>
            </trans-title-group>
            <alt-title alt-title-type="running-head" xml:lang="sl">Peritonitis pri bolnikih na peritonealni dializi</alt-title>
         </title-group>
         <contrib-group>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Janež</surname>
                  <given-names>Jurij</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
               <xref ref-type="corresp" rid="corr"/>
            </contrib>
            <contrib contrib-type="author" xlink:type="simple">
               <name name-style="western">
                  <surname>Čebron</surname>
                  <given-names>Žan</given-names>
               </name>
               <xref ref-type="aff" rid="aff1">1</xref>
            </contrib>
         </contrib-group>
         <aff-alternatives id="aff1">
            <aff xml:lang="sl">
               <label>1</label>
               <institution>Klinični oddelek za abdominalno kirurgijo, Kirurška klinika, Univerzitetni klinični center Ljubljana, Ljubljana, Slovenija</institution>
            </aff>
            <aff xml:lang="en">
               <label>1</label>
               <institution>Department of Abdominal Surgery, Division of Surgery, University Medical Centre Ljubljana, Ljubljana, Slovenia</institution>
            </aff>
         </aff-alternatives>
         <author-notes>
            <fn fn-type="conflict" xml:lang="en">
               <p>The authors have declared that no competing interests exist.</p>
            </fn>
            <fn fn-type="conflict" xml:lang="sl">
               <p>Avtorji so izjavili, da ne obstajajo nobeni konkurenčni interesi.</p>
            </fn>
            <corresp id="corr">Jurij Janež, e-mail: <email xlink:type="simple"/>
            </corresp>
         </author-notes>
         <pub-date pub-type="ppub">
            <month>2</month>
            <year>2019</year>
         </pub-date>
         <pub-date pub-type="epub">
            <month>2</month>
            <year>2019</year>
         </pub-date>
         <volume>88</volume>
         <issue>1–2</issue>
         <fpage>39</fpage>
         <lpage>49</lpage>
         <history>
            <date date-type="received">
               <day>26</day>
               <month>5</month>
               <year>2018</year>
            </date>
            <date date-type="accepted">
               <day>10</day>
               <month>2</month>
               <year>2019</year>
            </date>
         </history>
         <permissions>
            <copyright-statement xml:lang="en">Copyright © 2019, Slovenian Medical Association (SZD)</copyright-statement>
            <copyright-statement xml:lang="sl">© 2019, Slovensko zdravniško društvo (SZD)</copyright-statement>
            <copyright-year>2019</copyright-year>
            <copyright-holder xml:lang="en">Slovenian Medical Association (SZD)</copyright-holder>
            <copyright-holder xml:lang="sl">Slovensko zdravniško društvo (SZD)</copyright-holder>
            <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                     xlink:type="simple"
                     xml:lang="en">
               <license-p>This is an open access article distributed under the terms of the
          <ext-link ext-link-type="uri"
                            xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                            xlink:type="simple">Creative Commons Attribution-NonCommercial
            License</ext-link>, which permits unrestricted use, distribution, and
          reproduction in any medium, provided the original author and source are
          credited and only for non-commercial purposes. </license-p>
            </license>
            <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                     xlink:type="simple"
                     xml:lang="sl">
               <license-p>To je članek z odprtim dostopom, ki ga lahko uporabite pod pogoji iz
          <ext-link ext-link-type="uri"
                            xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                            xlink:type="simple">Creative Commons Priznanje avtorstva-Nekomercialno
            licence</ext-link>. ki dovoljuje distribucijo, predelavo ali
          prilagoditev, ter gradijo na njem, v nekomercialne namene, z navedbo avtorja
          in izvirnega dela.</license-p>
            </license>
         </permissions>
         <abstract xml:lang="sl">
            <title>Izvleček</title>
            <p>Peritonealna dializa se po vsem svetu uporablja za zdravljenje končne ledvične odpovedi. Ocenjuje se, da se z metodo peritonealne dialize zdravi več kot 200.000 bolnikov v več kot 130 državah, kar je približno 11 % vseh bolnikov na dializnem zdravljenju. V Sloveniji je bilo leta 2013 na nadomestnem zdravljenju zaradi končne ledvične odpovedi skupno 2.077 bolnikov, od tega 52 (2,5 %) na peritonealni dializi. Delež bolnikov, zdravljenih s peritonealno dializo, se je v Sloveniji v zadnjem desetletju zmanjšal predvsem na račun vedno večjega deleža bolnikov z delujočo in presajeno ledvico.</p>
            <p>Možen zaplet peritonealne dialize je pojav peritonitisa. Incidenca peritonitisa se ocenjuje na približno 0,4 epizode na bolnikovo leto zdravljenja. Smrtnost zaradi peritonitisa se je pri bolnikih na peritonealni dializi v zadnjih desetletjih zaradi preventivnih ukrepov pomembno zmanjšala. Manj kot 5 % epizod peritonitisa se konča s smrtjo, a ocenjuje se, da je peritonitis pomemben pridruženi dejavnik pri približno 16 % vseh smrti.</p>
            <p>Čas od nastanka peritonitisa do začetka zdravljenja pomembno vpliva na potek in napoved izida peritonitisa, zato je ob prepoznavi bolezni nujno takojšnje ukrepanje. Bolniki s peritonitisom potrebujejo konzervativno in/ali kirurško zdravljenje. Peritonitis zdravimo z odstranitvijo žarišča okužbe, izpiranjem trebušne votline z 0,9-odstotno raztopino NaCl ter uvedbo najprej empiričnega in nato usmerjenega protimikrobnega zdravljenja.</p>
            <p>Preprečevanje peritonitisa je velik izziv in je pomembno vsaj toliko, kot sta pomembna zgodnja diagnoza in zdravljenje.</p>
         </abstract>
         <trans-abstract xml:lang="en">
            <title>Abstract</title>
            <p>Peritoneal dialysis is used worldwide as a treatment for end-stage kidney failure. Globally, it accounts for about 11 % of all therapeutic dialysis interventions, with over 200.000 patients currently undergoing the procedure in more than 130 countries. In Slovenia, however, the percentage of patients treated by peritoneal dialysis has fallen due to the rise in renal transplantation services and the number of transplanted patients with functioning kidney graft. In 2013, patients receiving peritoneal dialysis in Slovenia accounted for only 2.5 % (52 patients) of the total number treated by renal replacement therapy (2077 patients).</p>
            <p>A potential complication of peritoneal dialysis is peritonitis. Although in general, peritonitis-related mortality has declined significantly in the last decade (with less than 5 % of peritonitis episodes resulting in death) possibly due to improved preventive measures, peritonitis still remains a direct or major contributing cause of mortality in approximately 16 % of peritoneal dialysis patients.</p>
            <p>In these patients, the time frame between the onset of peritonitis and the commencement of treatment critically determines the course and outcome of the disease. Peritonitis patients require urgent care, and therapeutic interventions may include conservative and/or surgical treatment protocols.</p>
            <p>Meanwhile, it is important to emphasize that prevention of peritoneal dialysis-associated peritonitis is as important as early diagnosis and timely treatment.</p>
         </trans-abstract>
         <kwd-group xml:lang="sl">
            <kwd>peritonitis</kwd>
            <kwd>peritonealna dializa</kwd>
            <kwd>zdravljenje</kwd>
            <kwd>preprečevanje</kwd>
         </kwd-group>
         <kwd-group xml:lang="en">
            <kwd>peritonitis</kwd>
            <kwd>peritoneal dialysis</kwd>
            <kwd>treatment</kwd>
            <kwd>prevention</kwd>
         </kwd-group>
         <custom-meta-group>
            <custom-meta>
               <meta-name>TotalReferences</meta-name>
               <meta-value>30</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ReferencesParsed</meta-name>
               <meta-value>26</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ReferencesBillable</meta-name>
               <meta-value>24</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>LinkServices</meta-name>
               <meta-value>pubmed-crossref</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ReferencesLinked</meta-name>
               <meta-value>19</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ReferencesLinkedDOI</meta-name>
               <meta-value>18</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ReferencesLinkedPMID</meta-name>
               <meta-value>19</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>JournalReferences</meta-name>
               <meta-value>22</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>BookReferences</meta-name>
               <meta-value>3</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>BookChapterReferences</meta-name>
               <meta-value>3</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ConferenceReferences</meta-name>
               <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ElectronicReferences</meta-name>
               <meta-value>2</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>DissertationReferences</meta-name>
               <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>LegalReferences</meta-name>
               <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>StandardReferences</meta-name>
               <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>OtherReferences</meta-name>
               <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>UnknownReferences</meta-name>
               <meta-value>1</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ReferencesSemiParsed</meta-name>
               <meta-value>0</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>ReferencesBookUnparsed</meta-name>
               <meta-value>3</meta-value>
            </custom-meta>
            <custom-meta>
               <meta-name>EditorialStyle</meta-name>
               <meta-value>ICMJE-WHO</meta-value>
            </custom-meta>
         </custom-meta-group>
      </article-meta>
   </front>
   <body>
      <sec id="s1" sec-type="Uvod">
         <label>1</label>
         <title>Uvod</title>
         <p>Peritonitis je akutno vnetje visceralnega in parietalnega lista potrebušnice, ki lahko hudo prizadene bolnika in ogroža njegovo življenje. Zaradi velike koncentracije bakterij v prebavilih in velike površine potrebušnice pogosto vodi v hudo sepso (<xref ref-type="bibr" rid="b1">1</xref>,<xref ref-type="bibr" rid="b2">2</xref>). Peritonitis je že od uvedbe peritonelne dialize (PD) po letu 1960 resen zaplet, ki poškoduje peritonealno membrano ter povzroča strukturne in funkcijske spremembe. Je najpogostejši razlog za sprejem v bolnišnico, odstranitev peritonealnega dializnega katetra in v 30–80 % celo za prekinitev peritonealne dialize. V Sloveniji se incidenca peritonitisa ocenjuje na približno 0,33 epizod na bolnikovo leto zdravljenja (ena epizoda na 36 bolnikovih mesecev zdravljenja) (<xref ref-type="bibr" rid="b3">3</xref>-<xref ref-type="bibr" rid="b6">6</xref>).</p>
      </sec>
      <sec id="s2" sec-type="Peritonitis">
         <label>2</label>
         <title>Peritonitis</title>
         <p>Peritonitis je vnetje visceralnega in parietalnega lista potrebušnice zaradi različnih vzrokov. Glede na vzrok in mehanizem nastanka peritonitisa ločimo primarni, sekundarni in terciarni (<xref ref-type="bibr" rid="b1">1</xref>,<xref ref-type="bibr" rid="b2">2</xref>). Primarni peritonitis, ki predstavlja približno 10 % vseh peritonitisov, je redko vnetje potrebušnice, pri katerem ne dokažemo patoloških sprememb v trebuhu. Najpogosteje se pojavlja pri otrocih, pri bolnikih z jetrno cirozo in ascitesom, pri nefrotskem sindromu in pri bolnikih s kongestivnim srčnim popuščanjem (<xref ref-type="bibr" rid="b2">2</xref>,<xref ref-type="bibr" rid="b7">7</xref>). Sekundarni peritonitis je najpogostejši (približno 80 %) in je posledica širjenja okužbe zaradi poškodbe ali vnetja znotraj trebuha. Do sekundarnega peritonitisa največkrat pride pri peptični ulkusni bolezni, akutnem vnetju slepiča, akutnem vnetju žolčnika in črevesnih divertiklih (<xref ref-type="bibr" rid="b2">2</xref>,<xref ref-type="bibr" rid="b8">8</xref>), kot zaplet pa se pojavlja tudi pri bolnikih na PD. Etiopatogeneza peritonitisa pri PD je opisana v nadaljevanju. Pri terciarnem peritonitisu (približno 10 %) gre za vztrajajoče vnetje potrebušnice z nizkovirulentnimi bakterijami ali glivami, čeprav je septično žarišče v trebuhu že pozdravljeno. Najpogosteje se to zgodi pri imunsko oslabelih bolnikih (<xref ref-type="bibr" rid="b1">1</xref>,<xref ref-type="bibr" rid="b8">8</xref>,<xref ref-type="bibr" rid="b9">9</xref>).</p>
         <p>Bolniki s peritonitisom potrebujejo konzervativno in/ali kirurško zdravljenje. Peritonitis zdravimo z odstranitvijo žarišča okužbe, izpiranjem trebušne votline z 0,9-odstotno raztopino NaCl ter uvedbo najprej empiričnega in nato usmerjenega antibiotičnega zdravljenja. Intenzivno pooperacijsko zdravljenje z infuzijami tekočin, nadomeščanjem elektrolitov, popravo presnovnih motenj in podporo vitalnih organov bistveno prispeva k uspešnosti zdravljenja. Pomembno je, da na peritonitis čim prej posumimo, potrdimo diagnozo in takoj začnemo zdravljenje. Čas od nastanka peritonitisa do začetka zdravljenja bistveno vpliva na potek in izid peritonitisa (<xref ref-type="bibr" rid="b1">1</xref>,<xref ref-type="bibr" rid="b2">2</xref>,<xref ref-type="bibr" rid="b10">10</xref>-<xref ref-type="bibr" rid="b13">13</xref>).</p>
      </sec>
      <sec id="s3" sec-type="Epidemiologija">
         <label>3</label>
         <title>Epidemiologija</title>
         <p>PD se po vsem svetu uporablja za zdravljenje končne ledvične odpovedi. Ocenjuje se, da se z metodo PD zdravi več kot 200.000 bolnikov v več kot 130 državah, kar je približno 11 % vseh bolnikov na dializnem zdravljenju (<xref ref-type="bibr" rid="b14">14</xref>). V ZDA je takih bolnikov približno 26.000 (<xref ref-type="bibr" rid="b15">15</xref>). V Sloveniji se je v zadnjem desetletju zmanjšala tako prevalenca kakor tudi delež bolnikov, zdravljenih s PD, ki je sedaj precej pod svetovnim povprečjem 11 % (<xref ref-type="bibr" rid="b16">16</xref>). Leta 2013 je bilo v Sloveniji od skupno 2.077 bolnikov na nadomestnem zdravljenju zaradi končne ledvične odpovedi le 52 bolnikov (2,5 %), ki se zdravijo s PD. Delež bolnikov na PD je upadel predvsem na račun vedno večjega deleža bolnikov z delujočo in presajeno ledvico (32,5 % vseh bolnikov) (<xref ref-type="bibr" rid="b17">17</xref>).</p>
         <p>Pogostost peritonitisa je bila v prvih letih uporabe PD zelo visoka, pogostost pa se je po uvedbi številnih ukrepov za preprečevanje peritonitisa bistveno zmanjšala. Na primer v ZDA je bila v letih 1980–1990 incidenca peritonitisa 1,1–1,3 epizod na bolnikovo leto zdravljenja, študije iz zadnjih let pa navajajo incidenco 0,4 epizod na bolnikovo leto zdravljenja (<xref ref-type="bibr" rid="b4">4</xref>).</p>
         <p>Čeprav se je v zadnjih letih incidenca peritonitisa zmanjševala, se podatki med različnimi državami ter tudi med različnimi centri znotraj istih držav zelo razlikujejo, saj je poročana incidenca 0,06–1,66 epizode na bolnikovo leto zdravljenja. Glavni vzroki za takšne razlike v incidenci so najverjetneje predvsem neupoštevanje priporočil za preprečevanje peritonitisa v posameznih centrih, različna populacija zdravljenih bolnikov ter nedoslednost pri zbiranju podatkov. Mednarodno združenje za peritonealno dializo (<italic toggle="yes">angl.</italic> 
            <italic toggle="yes">International Society for Peritoneal Dialysis - </italic>
            <italic toggle="yes">ISPD</italic>) meni, da pogostost peritonitisa v nobenem centru ne bi smela presegati 0,5 epizod na bolnikovo leto zdravljenja. V Sloveniji se incidenca peritonitisa ocenjuje na približno 0,33 epizod na bolnikovo leto zdravljenja (ena epizoda na 36 bolnikovih mesecev zdravljenja) (<xref ref-type="bibr" rid="b2">2</xref>-<xref ref-type="bibr" rid="b4">4</xref>,<xref ref-type="bibr" rid="b6">6</xref>,<xref ref-type="bibr" rid="b14">14</xref>,<xref ref-type="bibr" rid="b15">15</xref>,<xref ref-type="bibr" rid="b18">18</xref>).</p>
         <p>Za kakovostno zbiranje podatkov, ki se med posameznimi ustanovami lahko primerjajo in nato ocenjujejo kakovost dela posameznega centra, je ISPD izdal naslednja priporočila za spremljanje pogostosti peritonitisa pri PD. Vsak center, ki izvaja PD, mora beležiti letno incidenco peritonitisa. Svetuje se natančno beleženje, ali se je peritonitis pojavil že v bolnišnici kmalu po vstavitvi peritonealnega dializnega katetra ali šele po začetku izvajanja dialize na domu. Pri oblikovanju lokalnih priporočil za empirično protimikrobno zdravljenje so ključni podatki o povzročiteljih peritonitisa in njihova občutljivost na protimikrobna zdravila. Zaželeno je tudi beleženje števila bolnikov, ki v zadnjem letu niso imeli nobene epizode peritonitisa, in števila bolnikov, ki so zaradi peritonitisa umrli (smrt med bolnišničnim zdravljenjem zaradi peritonitisa ali smrt znotraj štirih tednov po začetku peritonitisa) (<xref ref-type="bibr" rid="b4">4</xref>).</p>
      </sec>
      <sec id="s4" sec-type="Etiopatogeneza">
         <label>4</label>
         <title>Etiopatogeneza</title>
         <p>Možnih je več poti okužbe:</p>
         <list>
            <list-item>
               <label>•</label>
               <p>intraluminalno – do okužbe pride skozi peritonealni dializni kateter zaradi okužbe pri menjavi vrečk ali zaradi bakterij v dializni raztopini;</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>periluminalno – do okužbe pride ob katetru skozi trebušno steno;</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>transmuralno – do okužbe pride zaradi translokacije bakterij iz črevesa;</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>ascendentno – do okužbe pride, če obstaja povezava med nožnico in peritonealno votlino skozi jajcevode ali fistule;</p>
            </list-item>
            <list-item>
               <label>•</label>
               <p>hematogeno.</p>
            </list-item>
         </list>
         <p>Najpogostejša je intraluminalna pot okužbe. Periluminalna pot je redek vzrok okužbe zaradi napredka in izboljšav pri vstavljanju dializnega katetra, saj imajo dializni katetri dvojno objemko, ki preprečuje vdor bakterij v peritonealno votlino. Ostale poti okužbe so še redkejše (<xref ref-type="bibr" rid="b3">3</xref>,<xref ref-type="bibr" rid="b19">19</xref>,<xref ref-type="bibr" rid="b20">20</xref>).</p>
         <p>Globalno gledano približno 75 % okužb povzročajo po Gramu-pozitivne bakterije, najpogostejša povzročitelja sta <italic toggle="yes">S. epidermidis</italic> (30–50 % vseh okužb) in <italic toggle="yes">S. aureus</italic>, ki sta normalno prisotna na koži in lahko prideta v trebušno votlino preko intraluminalne poti zaradi nesterilnega rokovanja s spoji katetra. Drugi pogosti povzročitelji so še koagulazno negativni stafilokoki<italic toggle="yes">, E. coli</italic>, <italic toggle="yes">P. aeruginosa</italic> in glive (predvsem <italic toggle="yes">Candida spp.</italic>) (<xref ref-type="bibr" rid="b2">2</xref>,<xref ref-type="bibr" rid="b3">3</xref>,<xref ref-type="bibr" rid="b19">19</xref>). Etiološki podatki se sicer nekoliko razlikujejo glede na geografsko lego, npr. v Indiji je peritonitis zaradi okužbe s po Gramu negativnimi bakterijami bolj pogost od peritonitisa s po Gramu pozitivnimi bakterijami, kar vpliva na slabši izid zdravljenja. Med povzročitelji, ki povzročajo doma ali v bolnišnici nastali peritonitis, ni pomembnih razlik (<xref ref-type="bibr" rid="b19">19</xref>,<xref ref-type="bibr" rid="b21">21</xref>).</p>
      </sec>
      <sec id="s5" sec-type="Klinična slika">
         <label>5</label>
         <title>Klinična slika</title>
         <p>Peritonitis je pogost zaplet PD. Najpomembnejši simptom so difuzne bolečine v trebuhu, najpomembnejši znak je môten dializat (<xref ref-type="bibr" rid="b12">12</xref>,<xref ref-type="bibr" rid="b18">18</xref>). Moten dializat skoraj vedno pomeni infekcijski peritonitis, ostali vzroki motnega dializata so namreč izjemno redki (npr. kemični peritonitis, antagonisti kalcijevih kanalčkov, maligna bolezen, hematoperitonej ter drugi) (<xref ref-type="bibr" rid="b4">4</xref>). Pri hudem peritonitisu so lahko navzoči še drugi simptomi in znaki, kot so povišana telesna temperatura, slabost, bruhanje, driska in motnje pri iztoku dializata (<xref ref-type="bibr" rid="b3">3</xref>).</p>
      </sec>
      <sec id="s6" sec-type="Diagnoza">
         <label>6</label>
         <title>Diagnoza</title>
         <p>Za potrditev diagnoze peritonitisa morata biti izpolnjena dva od treh naštetih meril:</p>
         <list>
            <list-item>
               <label>1.</label>
               <p>prisotnost kliničnih znakov peritonitisa (npr. občutljivost ali bolečina v trebuhu);</p>
            </list-item>
            <list-item>
               <label>2.</label>
               <p>moten peritonealni izpirek z več kot 0,1 × 10<sup>9</sup>/L levkocitov, od tega več kot 50 % nevtrofilcev;</p>
            </list-item>
            <list-item>
               <label>3.</label>
               <p>dokazani mikrobi iz peritonealnega izpirka (<xref ref-type="bibr" rid="b3">3</xref>,<xref ref-type="bibr" rid="b4">4</xref>).</p>
            </list-item>
         </list>
         <p>Za hitrejše določanje, ali peritonitis povzročajo po Gramu pozitivne ali po Gramu negativne bakterije, se lahko odločimo, da izpirek barvamo po Gramu, vendar je ta metoda zelo slabo občutljiva, saj zaznamo le 10–40 % okuženih vzorcev (<xref ref-type="bibr" rid="b2">2</xref>). V primeru bolečin v trebuhu in bistrega izpirka moramo pri bolnikih na PD v diferencialno diagnozo bolečin vedno vključiti tudi peritonitis (<xref ref-type="bibr" rid="b4">4</xref>).</p>
         <p>Slikovne preiskave pri postavitvi diagnoze nimajo pravega pomena, so pa nam v veliko pomoč pri izključevanju ostalih možnih vzrokov peritonitisa, ki bi glede na bolnikovo klinično sliko bili možni (<xref ref-type="bibr" rid="b11">11</xref>,<xref ref-type="bibr" rid="b12">12</xref>). Če pri bolniku na PD s slikovnimi preiskavami ugotovimo prosti zrak v trebuhu, je to neodvisni dejavnik tveganja za peritonitis, zato je tako pri bistrem kot pri motnem peritonealnem izpirku potrebno opraviti prej naštete preiskave za potrditev ali izključitev peritonitisa (<xref ref-type="bibr" rid="b22">22</xref>). Za oceno debeline peritonealne membrane, ki vpliva na učinkovitost PD, se lahko namesto invazivnih metod uporablja ultrazvočna preiskava (UZ) (<xref ref-type="bibr" rid="b23">23</xref>).</p>
      </sec>
      <sec id="s7" sec-type="Zdravljenje">
         <label>7</label>
         <title>Zdravljenje</title>
         <p>Ko je verjetnost peritonitisa pri bolnikih na PD zelo verjetna ali potrjena, si ogledamo izstopišče peritonealnega katetra ter ocenimo, ali so prisotni znaki vnetja. Nato odvzamemo vzorec izpirka in ga pošljemo na nadaljnje preiskave. Z začetnim empiričnim antibiotičnim zdravljenjem ne odlašamo in začnemo takoj, saj lahko odlaganje zdravljenja pomembno vpliva na potek in izid peritonitisa. ISPD svetuje prekinitev PD za vsaj 6–48 ur po prvem odmerku protimikrobnega zdravila. Glede tega so mnenja deljena, saj prekinitev PD pomeni, da bo bolnik potreboval hemodializo, ki tudi ima svoja tveganja in zaplete. V literaturi zato nekateri avtorji svetujejo, da se PD ne prekinja, razen v primeru, ko je potrebna odstranitev peritonealnega katetra. Pri vsakem bolniku ocenimo, ali je potrebna dodatno zdravljenje z analgetiki, intraperitonealnim vnosom heparina in profilaktičnim antimikotikom. Bolnika je potrebno pred odpustom izobraziti o načinu intraperitonealnega dajanja zdravil ter ga naročiti na redne kontrolne preglede. Smiselno je, da se preveri pravilnost izvajanja PD in se bolnika opozori o domnevnih napakah pri izvajanju PD. Začetni ukrepi pri peritonitisu so predstavljeni v <xref ref-type="fig" rid="fig1">Sliki 1</xref> (<xref ref-type="bibr" rid="b4">4</xref>).</p>
         <fig position="anchor" id="fig1" orientation="portrait">
            <label>Slika 1:</label>
            <caption>
               <p> Začetno zdravljenje pri peritonitisu; IP – intraperitonealno; prirejeno po ISPD smernicah (<xref ref-type="bibr" rid="b4">4</xref>).</p>
            </caption>
            <p>
               <graphic xlink:href="2844-web-resources/image/zdravvestn-2844-sl-01.png"
                        position="float"
                        orientation="portrait"/>
            </p>
         </fig>
         <sec id="s7.1" sec-type="Izbira in odmerjanje antibiotika">
            <label>7.1</label>
            <title>Izbira in odmerjanje antibiotika</title>
            <p>Začetno empirično zdravljenje mora pokriti tako po Gramu pozitivne kot po Gramu negativne povzročitelje. Priporočila ISPD so, da se za po Gramu pozitivne povzročitelje dajejo vankomicin ali cefalosporini prve generacije (npr. cefazolin), za po Gramu negativne pa cefalosporine tretje generacije (npr. cefepim, ceftazidim) ali aminoglikozid (npr. gentamicin). Bolj kot upoštevanje priporočil ISPD je pomembno upoštevanje občutljivosti lokalnih povzročiteljev na antibiotike ter na predhodne izkušnje posameznega dializnega centra. V Sloveniji imamo največ dobrih izkušenj z intraperitonealnim zdravljenjem s cefazolinom in gentamicinom (glej Algoritem 1). Po prejemu izvida bakterijskih kultur in antibiograma antibiotično zdravljenje po potrebi prilagodimo. Zgolj s protimikrobnim zdravljenjem brez drugih ukrepov uspemo pozdraviti približno 75 % peritonitisov. Uspešnost protimikrobnega zdravljenja brez odstranitve katetra je v veliki meri odvisna od povzročitelja in je za posamezne povzročitelje naslednja – koagulazno negativni stafilokoki 90 %, <italic toggle="yes">S. aureus</italic> 66 %, G-negativni bacili 56 % in glive 0 %. Če pri bolniku ne pride do izboljšanja kliničnega stanja in do zbistritve izpirka v petih dneh, peritonealni kateter odstranimo. Včasih peritonealni kateter odstranimo prej kot v petih dneh; indikacije za odstranitev peritonealnega katetra so opisane v nadaljevanju. Če je bolnik ogrožen, ima znake sepse in/ali znake okužbe izstopišča peritonealnega katetra, dodamo sistemski antibiotik intravensko, empirično izberemo vankomicin in ceftazidim, sicer pa antibiotik izberemo glede na povzročitelje in antibiogram. Priporočeni odmerki za intraperitonealno dajanje pogosteje uporabljenih antibiotikov so predstavljeni v <xref ref-type="table" rid="table1">Tabeli 1</xref> (<xref ref-type="bibr" rid="b2">2</xref>-<xref ref-type="bibr" rid="b4">4</xref>,<xref ref-type="bibr" rid="b19">19</xref>,<xref ref-type="bibr" rid="b24">24</xref>).</p>
            <table-wrap position="anchor" id="table1" orientation="portrait">
               <label>Tabela 1:</label>
               <caption>
                  <p> Odmerki pogosteje uporabljenih antibiotikov za zdravljenje peritonitisa pri PD, prirejeno po smernicah ISPD (<xref ref-type="bibr" rid="b4">4</xref>). LD – polnitveni odmerek (<italic toggle="yes">angl.</italic> loading dose), MD – vzdrževalni odmerek (<italic toggle="yes">angl.</italic> maintenance dose) </p>
               </caption>
               <table>
                  <colgroup span="1">
                     <col span="1"/>
                     <col span="1"/>
                     <col span="1"/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th rowspan="1" colspan="1">Antibiotik</th>
                        <th rowspan="1" colspan="1">Intermitentno (1 izmenjava)</th>
                        <th rowspan="1" colspan="1">Kontinuirano (vse izmenjave)</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td rowspan="1" colspan="1">Gentamicin</td>
                        <td rowspan="1" colspan="1">0,6 mg/kg na dan</td>
                        <td rowspan="1" colspan="1">LD 25 mg/L, MD 12 mg/L</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Amikacin</td>
                        <td rowspan="1" colspan="1">2 mg/kg na dan</td>
                        <td rowspan="1" colspan="1">LD 8 mg/L, MD 4 mg/L</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Cefazolin</td>
                        <td rowspan="1" colspan="1">15–20 mg/kg na dan</td>
                        <td rowspan="1" colspan="1">LD 500 mg/L, MD 125 mg/L</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Ceftriakson</td>
                        <td rowspan="1" colspan="1">1,000 mg na dan</td>
                        <td rowspan="1" colspan="1">ni podatka</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Cefotaksim</td>
                        <td rowspan="1" colspan="1">500–1,000 mg na dan</td>
                        <td rowspan="1" colspan="1">ni podatka</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Ceftazidim</td>
                        <td rowspan="1" colspan="1">1,000–1,500 mg na dan</td>
                        <td rowspan="1" colspan="1">LD 500 mg/L, MD 125 mg/L</td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Vankomicin</td>
                        <td rowspan="1" colspan="1">15–30 mg/kg na 5–7 dni</td>
                        <td rowspan="1" colspan="1">LD 30 mg/kg, MD 1,5 mg/kg/vrečka</td>
                     </tr>
                  </tbody>
               </table>
            </table-wrap>
         </sec>
         <sec id="s7.2" sec-type="Trajanje zdravljenja">
            <label>7.2</label>
            <title>Trajanje zdravljenja</title>
            <p>Trajanje zdravljenja je odvisno od povzročitelja. Za priporočeno trajanje zdravljenja pri posameznih povzročiteljih glej <xref ref-type="table" rid="table2">Tabelo 2</xref> (<xref ref-type="bibr" rid="b3">3</xref>,<xref ref-type="bibr" rid="b4">4</xref>).</p>
            <table-wrap position="anchor" id="table2" orientation="portrait">
               <label>Tabela 2:</label>
               <caption>
                  <p> Čas zdravljenja in druge posebnosti zdravljenja za posamezne povzročitelje peritonitisa, prirejeno po smernicah ISPD (<xref ref-type="bibr" rid="b4">4</xref>). </p>
               </caption>
               <table>
                  <colgroup span="1">
                     <col span="1"/>
                     <col span="1"/>
                  </colgroup>
                  <thead>
                     <tr>
                        <th rowspan="1" colspan="1">Povzročitelj</th>
                        <th rowspan="1" colspan="1">Priporočila</th>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td rowspan="1" colspan="1">Koagulazno negativni stafilokoki</td>
                        <td rowspan="1" colspan="1">
                           <p>Zdravljenje z IP cefalosporini ali vankomicinom glede na lokalno občutljivost mikroorganizmov.</p>
                           <p>Čas zdravljenja 2 tedna.</p>
                        </td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Enterococuss spp.</td>
                        <td rowspan="1" colspan="1">
                           <p>Zdravljenje z IP vankomicinom. Za zdravljenje hudega peritonitisa IP aminoglikozidi.</p>
                           <p>Čas zdravljenja 3 tedne.</p>
                           <p>*Izjema VRE (<italic toggle="yes">angl.</italic>
                              <italic toggle="yes"> </italic>vankomicin-resistant Enterococcus) – zdravljenje z IP ampicilin. V primeru odpornosti na ampicilin zdravljenje glede na antibiogram (npr. linezolid, teikoplanin…).</p>
                        </td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Streptococcus spp.</td>
                        <td rowspan="1" colspan="1">
                           <p>Zdravljenje z IP ampicilinom.</p>
                           <p>Čas zdravljenja 2 tedna.</p>
                        </td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">S. aureus</td>
                        <td rowspan="1" colspan="1">
                           <p>Zdravljenje z lokalno učinkovitim antibiotikom.</p>
                           <p>Čas zdravljenja 3 tedne.</p>
                        </td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Corynebacterium spp.</td>
                        <td rowspan="1" colspan="1">
                           <p>Zdravljenje z lokalno učinkovitim antibiotikom.</p>
                           <p>Čas zdravljenja 3 tedne.</p>
                        </td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Pseudomonas spp.</td>
                        <td rowspan="1" colspan="1">
                           <p>Zdravljenje z dvema antibiotikoma, ki imata različen mehanizem delovanja. (npr. IP gentamicin ali oralno ciprofloksacin z IP cefazidimom ali cefepimom).</p>
                           <p>Čas zdravljenja 3 tedne.</p>
                           <p>V primeru okužbe vstopnega mesta odstranitev dializnega katetra.</p>
                        </td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Druge gram negativne bakterije</td>
                        <td rowspan="1" colspan="1">
                           <p>Zdravljenje z lokalno učinkovitim antibiotikom.</p>
                           <p>Čas zdravljenja 3 tedne.</p>
                        </td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Polimikrobni peritonitis</td>
                        <td rowspan="1" colspan="1">
                           <p>Mikroorganizmi črevesne flore</p>
                           <p>Če ni odziva na začetno empirično zdravljenje, opravimo slikovno diagnostiko (UZ, CT trebuha) in se posvetujemo s kirurgom.</p>
                           <p>Zdravljenje z metronidazolom, IP vankomicinom in IP aminoglikozidi ali IP cefazidimom.</p>
                           <p>Čas zdravljenja najmanj 3 tedne.</p>
                           <p>Več po Gramu pozitivnih mikroorganizmov</p>
                           <p>Zdravljenje z lokalno učinkovitim antibiotikom.</p>
                           <p>Čas zdravljenja 3 tedne.</p>
                        </td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Peritonitis z negativnimi kulturami</td>
                        <td rowspan="1" colspan="1">
                           <p>Ponovni odvzem vzorca izpirka po treh dneh zdravljenja. Ob izboljšanju izvidov izpirka lahko zožimo spekter antibiotičnega zdravljenja (npr. aminoglikozide zamenjamo za cefalosporine prve generacije ali vankomicin).</p>
                           <p>Čas zdravljenja 2 tedna.</p>
                        </td>
                     </tr>
                     <tr>
                        <td rowspan="1" colspan="1">Glivni peritonitis</td>
                        <td rowspan="1" colspan="1">
                           <p>Takojšnja odstranitev dializnega katetra.</p>
                           <p>Zdravljenje z lokalno učinkovitim antimikotikom.</p>
                           <p>Čas zdravljenja vsaj 2 tedna.</p>
                        </td>
                     </tr>
                  </tbody>
               </table>
            </table-wrap>
         </sec>
         <sec id="s7.3" sec-type="Ocena uspešnosti zdravljenja">
            <label>7.3</label>
            <title>Ocena uspešnosti zdravljenja</title>
            <p>Bolnike po pričetku zdravljenja redno spremljamo in ocenjujemo, ali se njihovo klinično stanje izboljšuje. Klinično izboljšanje in vsaj delno zbistritev motnega izpirka pričakujemo znotraj 48 ur po pričetku zdravljenja; takrat določamo število levkocitov in odstotek nevtrofilcev v izpirku. Če se njihovo število po treh dneh zdravljenja ne zmanjša, je verjetnost, da bo zdravljenje učinkovito, manjša od 64 % (<xref ref-type="bibr" rid="b11">11</xref>,<xref ref-type="bibr" rid="b25">25</xref>). V tovrstnih primerih je smiselno intermitentno dajanje antibiotika zamenjati s kontinuiranimi. Če to ni mogoče, povečamo odmerek in pogostost izmenjave antibiotika (<xref ref-type="bibr" rid="b11">11</xref>).</p>
         </sec>
         <sec id="s7.4" sec-type="Indikacije za odstranitev in zamenjavo katetra">
            <label>7.4</label>
            <title>Indikacije za odstranitev in zamenjavo katetra</title>
            <p>Včasih protimikrobno zdravljenje ni učinkovito pri zdravljenju peritonitisa, zato moramo razmišljati o odstranitvi peritonealnega katetra. Zgodnja odstranitev katetra ob neučinkovitem protimikrobnem zdravljenju zmanjšuje smrtnost in trajanje epizode peritonitisa. Indikacije za odstranitev peritonealnega katetra so:</p>
            <list>
               <list-item>
                  <label>•</label>
                  <p>refraktarni peritonitis (ni pričakovanega odgovora na antibiotično zdravljenje v roku 5 dni);</p>
               </list-item>
               <list-item>
                  <label>•</label>
                  <p>ponavljajoči se peritonitis (ponovitev peritonitisa v roku štirih tednov);</p>
               </list-item>
               <list-item>
                  <label>•</label>
                  <p>glivni ali mikobakterijski peritonitis;</p>
               </list-item>
               <list-item>
                  <label>•</label>
                  <p>peritonitis, ki se pojavi ob drugih patoloških stanjih v trebuhu (npr. absces, perforacija…);</p>
               </list-item>
               <list-item>
                  <label>•</label>
                  <p>peritonitis z negativnimi mikrobiološkimi kulturami z vztrajajočimi povišanimi vrednostmi levkocitov v izpirku.</p>
               </list-item>
            </list>
            <p>Zamenjava peritonealnega katetra je možna pri ponavljajočem se peritonitisu, če pride po začetnem zdravljenju do zbistritve izpirka. V ostalih primerih stari kateter odstranimo in novega ne vstavljamo takoj, temveč je potrebno vsaj dvotedensko zdravljenje s sistemskim protimikrobnim zdravilom. Ponovno vstavitev katetra lahko izvedemo šele 2–4 tedne po odstranitvi, ko simptomi peritonitisa popolnoma izzvenijo (<xref ref-type="bibr" rid="b4">4</xref>,<xref ref-type="bibr" rid="b11">11</xref>,<xref ref-type="bibr" rid="b12">12</xref>).</p>
         </sec>
         <sec id="s7.5" sec-type="Dodatno zdravljenje in posebnosti">
            <label>7.5</label>
            <title>Dodatno zdravljenje in posebnosti</title>
            <p>Včasih lahko bolnike s peritonitisom zdravimo tudi doma. Odločitev za sprejem v bolnišnico temelji na hemodinamski stabilnosti bolnika ter izraženosti simptomov in znakov. Ob prisotnosti hudih bolečin moramo bolniku omogočiti zadostno količino analgetikov. ISPD priporoča profilaktično dajanje sistemskega antimikotika, saj so okužbe z glivami trdovratne za zdravljenje in praktično vedno zahtevajo odstranitev dializnega katetra, najpogosteje pa se pojavijo prav med antibiotičnim zdravljenjem. Pri bolnikih z motnim ascitesom se svetuje intraperitonealno dajanje 500 enot/L heparina, ki preprečuje zamašitev katetra s fibrinom (<xref ref-type="bibr" rid="b4">4</xref>).</p>
         </sec>
      </sec>
      <sec id="s8" sec-type="Preprečevanje">
         <label>8</label>
         <title>Preprečevanje</title>
         <p>Preprečevanje peritonitisa je velik izziv in je pomembno vsaj toliko, kot sta pomembna zgodnja diagnoza in zdravljenje. Vsak center, ki svojim bolnikom ponuja PD, mora redno spremljati in analizirati pogostost peritonitisa pri bolnikih ter zagotavljati ustrezne ukrepe za preprečevanje (<xref ref-type="bibr" rid="b3">3</xref>,<xref ref-type="bibr" rid="b5">5</xref>,<xref ref-type="bibr" rid="b26">26</xref>).</p>
         <p>ISPD je leta 2016 v posodobljenih smernicah podal naslednja priporočila za preprečevanje peritonitisa pri PD.</p>
         <p>Vstavitev dializnega katetra. Uporaba parenteralnega profilaktičnega antibiotičnega odmerka pred vstavitvijo peritonealnega katetra dokazano zmanjša pogostost zgodnjega peritonitisa. Glede na opravljene študije se svetuje uporaba cefalosporinov, gentamicina in vankomicina, pri izbiri antibiotika pa je potrebno upoštevati lokalno občutljivost bakterij. V Univerzitetnem kliničnem centru Ljubljana (UKC LJ) dajemo kot antibiotično profilakso cefazolin 2 g v enkratnem odmerku 30–60 min pred kirurškim rezom. Pri bolnikih s povečano telesno maso se včasih odločimo za večji odmerek, torej 3 g (<xref ref-type="bibr" rid="b27">27</xref>,<xref ref-type="bibr" rid="b28">28</xref>). Tehnika vstavitve katetra ne vpliva na pogostost peritonitisa (<xref ref-type="bibr" rid="b4">4</xref>,<xref ref-type="bibr" rid="b5">5</xref>,<xref ref-type="bibr" rid="b18">18</xref>,<xref ref-type="bibr" rid="b19">19</xref>,<xref ref-type="bibr" rid="b26">26</xref>,<xref ref-type="bibr" rid="b29">29</xref>). V UKC LJ zadnjih nekaj let vstavljamo peritonealne dializne katetre izključno laparoskopsko. V letu 2016 smo jih vstavili 22, pomembnejših zgodnjih zapletov pa nismo beležili (<xref ref-type="bibr" rid="b27">27</xref>).</p>
         <p>Oblika dializnega katetra. Poznamo več vrst in oblik katetrov – ravne, zavite in katetre v obliki labodjega vratu. Večinoma so ti katetri iz silikona, poznamo pa tudi poliuretanske. Največkrat se uporabljajo katetri z dvema dakronskima balončkoma, ki se po vstavitvi vrasteta v trebušno steno in poskrbita za dobro učvrstitev katetra (<xref ref-type="bibr" rid="b27">27</xref>). Več študij je primerjalo pogostost peritonitisa pri ravnih in zavitih katetrih, pomembnih razlik v pogostosti pa ni bilo (<xref ref-type="bibr" rid="b4">4</xref>).</p>
         <p>Metoda dializiranja. Uporabljamo izključno sistem z dvojnimi vrečkami, saj je pri tovrstnem načinu pogostost peritonitisa za približno 30 % nižja v primerjavi z drugimi metodami (<xref ref-type="bibr" rid="b3">3</xref>,<xref ref-type="bibr" rid="b4">4</xref>,<xref ref-type="bibr" rid="b6">6</xref>,<xref ref-type="bibr" rid="b18">18</xref>).</p>
         <p>Izobraževanje bolnikov in bolnikovih svojcev. Dializno osebje z dolgoletnimi izkušnjami mora zagotoviti, da se bolnik in njegovi svojci naučijo pravilnega izvajanja peritonealne dialize, saj kakovost izobraževanja zelo pomembno vpliva na pogostost peritonitisa. Žal še nimamo z dokazi podprtih priporočil, ki bi jasno opredeljevali, kdaj, kje in kako pogosto je potrebno izvajati izobraževanje. Vsekakor je pomembno, da po začetku izvajanja PD dializno osebje, ki ima izkušnje na področju peritonealne dialize, obišče bolnika in opazuje pravilnost izvajanja dialize ter bolnika opozori na nepravilnosti (<xref ref-type="bibr" rid="b3">3</xref>-<xref ref-type="bibr" rid="b5">5</xref>,<xref ref-type="bibr" rid="b26">26</xref>).</p>
         <p>Dializna raztopina. Več študij je raziskovalo vpliv različnih dializnih raztopin, ki so v uporabi. Obstajajo domneve, da so raztopine z manjšimi koncentracijami glukoznih razpadnih produktov bolj biokompatibilne z manjšim vplivom na pojav vnetja v primerjavi z ostalimi dializnimi raztopinami. Vendar je za potrditev domnev potrebnih več raziskav; zaenkrat velja mnenje, da vrsta raztopine ne vpliva na pogostost peritonitisa (<xref ref-type="bibr" rid="b4">4</xref>,<xref ref-type="bibr" rid="b18">18</xref>,<xref ref-type="bibr" rid="b30">30</xref>).</p>
         <p>Oskrba izstopišča peritonealnega katetra. Priporoča se, da se vstopno mesto enkrat na dan namaže s topičnim antibiotičnim mazilom. Ob izvajanju dialize se mora poskrbeti za ustrezno higieno rok. Uporaba obrazne maske ni obvezna, je pa vsekakor priporočljiva in jo svetujemo (<xref ref-type="bibr" rid="b3">3</xref>-<xref ref-type="bibr" rid="b5">5</xref>).</p>
         <p>Antibiotična profilaksa pred posegi. Glede na povečano tveganje za razvoj peritonitisa po posegih pri bolnikih na PD se svetuje profilaktična uporaba antibiotika pred kolonoskopijo in ginekološkimi posegi (<xref ref-type="bibr" rid="b4">4</xref>).</p>
      </sec>
      <sec id="s9" sec-type="Napoved izida">
         <label>9</label>
         <title>Napoved izida</title>
         <p>Čeprav se je smrtnost pri bolnikih na PD v zadnjih letih zmanjšala, je dolgoročno preživetje sorazmerno slabo (<xref ref-type="bibr" rid="b11">11</xref>,<xref ref-type="bibr" rid="b15">15</xref>). Enoletno preživetje je približno 86 %, desetletno preživetje pa znaša le približno 11 % (<xref ref-type="bibr" rid="b15">15</xref>). Vzrok nizkega desetletnega preživetja je posledica več dejavnikov in je odvisen od bolnikovih lastnosti in od dejavnikov dializnega centra (<xref ref-type="bibr" rid="b15">15</xref>). Potrebno je poudariti, da so podatki o dolgoročnem preživetju lahko zavajajoči in je potrebna pazljivost pri njihovi interpretaciji, saj se bolniki s PD redko zdravijo več kot 5 let. Pogosto namreč pride do prehoda na drugo obliko nadomestnega zdravljenja, kar veliko analiz obravnava kot neuspeh PD in to upošteva pri oceni dolgoročnega preživetja. V Sloveniji je v letu 2013 umrlo 12,3 % bolnikov na PD (<xref ref-type="bibr" rid="b17">17</xref>).</p>
         <p>Znanih je več dejavnikov, ki vplivajo na preživetje pri bolnikih na PD. Veliko dejavnikov, kot so na primer starost, sladkorna bolezen in etiologija kronične ledvične odpovedi, je nespremenljivih in nanje ne moremo vplivati. Pozornost moramo usmeriti k spremenljivim dejavnikom, ki vplivajo na dolgoročno napoved izida. To so predvsem preostala ledvična funkcija, ohranjena integriteta in funkcija peritonealne membrane ter peritonitis. Svetuje se, da vsem bolnikom s hipertenzijo in tudi brez nje, ki zdravljenje z zaviralci angiotenzin konvertaze (ACEI) dobro prenašajo, predpišemo ACEI, saj ACEI pomagajo pri ohranjanju preostale ledvične funkcije. Preostala ledvična funkcija je dober napovedni dejavnik, ki napoveduje boljši izid tako pri bolnikih na PD in pri tistih na hemodializi. Ena od študij je ugotovila povezavo, da se za vsakih 250 ml preostalega urina za približno 36 % zmanjša tveganje za 2-letno smrtnost (<xref ref-type="bibr" rid="b15">15</xref>). Srčno-žilni vzroki so najpogostejši vzroki za smrt pri bolnikih na PD (<xref ref-type="bibr" rid="b18">18</xref>).</p>
         <p>Smrtnost zaradi peritonitisa se je pri bolnikih na PD v zadnjih desetletjih zaradi preventivnih ukrepov za preprečevanje peritonitisa bistveno zmanjšala. Delež uspešno pozdravljenih peritonitisov ostaja visok in stabilen kljub vedno večji odpornosti mikroorganizmov na protimikrobna zdravila. Manj kot 5 % epizod peritonitisa se konča s smrtjo, a ocenjuje se, da je peritonitis pomemben pridruženi dejavnik pri približno 16 % vseh smrti. Po epizodi peritonitisa se poveča tveganje za smrt zaradi okužbe, pridruženih srčno-žilnih bolezni in prekinitve PD. Peritonitis je najpogostejši vzrok za odstranitev peritonealnega katetra, prekinitev PD in prehod na trajno hemodializno zdravljenje (<xref ref-type="bibr" rid="b4">4</xref>,<xref ref-type="bibr" rid="b6">6</xref>,<xref ref-type="bibr" rid="b18">18</xref>).</p>
      </sec>
      <sec id="s10" sec-type="Zaključek">
         <label>10</label>
         <title>Zaključek</title>
         <p>Peritonitis je možen in resen zaplet PD, ki lahko hudo prizadene bolnika in ogroža njegovo življenje. Čas od nastanka peritonitisa do začetka zdravljenja bistveno vpliva na potek in napoved izida peritonitisa, zato je nujno takojšnje ukrepanje. Peritonitis zdravimo z odstranitvijo žarišča okužbe, izpiranjem trebušne votline z 0,9-odstotno raztopino NaCl ter uvedbo najprej empiričnega in nato usmerjenega protimikrobnega zdravljenja. Peritonitis je najpogostejši vzrok za odstranitev peritonealnega katetra, prekinitev PD in prehod na trajno hemodializno zdravljenje, zato mora biti preprečevanje peritonitisa glavni namen vsakega dializnega centra. Poseben poudarek moramo nameniti izobraževanju bolnika in bolnikovih svojcev, še posebej po epizodi peritonitisa, saj je pogost vzrok peritonitisa ravno neustrezno rokovanje s peritonealnim katetrom.</p>
      </sec>
   </body>
   <back>
      <ref-list>
         <ref id="b1">
            <label>1. </label>
            <mixed-citation publication-type="book-chapter" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Omejc</surname> 
                     <given-names>M</given-names>
                  </string-name>
               </person-group>. <chapter-title>Kirurgija trebušne votline</chapter-title>. In: <person-group person-group-type="editor">
                  <string-name name-style="western">
                     <surname>Smrkolj</surname> 
                     <given-names>V</given-names>
                  </string-name>, <role>editor</role>
               </person-group>. <source>Kirurgija. Celje: Grafika Gracer</source>. <year>2014</year>. pp. <fpage>1000</fpage>–<lpage>2</lpage>.<annotation>
                  <p content-type="warning">Could not find a publisher location in this book chapter reference. (Ref. 1 "Omejc, 2014")</p>
                  <p content-type="warning">Could not find a publisher name in this book chapter reference. (Ref. 1 "Omejc, 2014")</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b2">
            <label>2. </label>
            <mixed-citation publication-type="book" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Townsend</surname> 
                     <given-names>C</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Beauchamp</surname> 
                     <given-names>RD</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Evers</surname> 
                     <given-names>BM</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Mattox</surname> 
                     <given-names>K</given-names>
                  </string-name>
               </person-group>. <source>Sabiston Textbook of Surgery: the Biological Basis of Modern Surgical Practice</source>. <publisher-loc>Amsterdam</publisher-loc>: <publisher-name>Elsevier</publisher-name>; <year>2017</year>.</mixed-citation>
         </ref>
         <ref id="b3">
            <label>3.	</label>
            <mixed-citation publication-type="book" specific-use="unparsed">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Košnik</surname> 
                     <given-names>M</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Mrevlje</surname> 
                     <given-names>F</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Štajer</surname> 
                     <given-names>D</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Černelč</surname> 
                     <given-names>P</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Koželj</surname> 
                     <given-names>M</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Andoljšek</surname> 
                     <given-names>D</given-names>
                  </string-name>, <etal>et al.</etal>
               </person-group> 
               <source>Interna medicina.</source> Ljubljana: Littera picta: Slovensko medicinsko društvo; <year>2011</year>. p. 1133-1137.<annotation>
                  <p content-type="warning">Edifix Bibliographic Reference Processing failed to fully style this reference. Please check the copyediting. (Ref. 3 "Košnik, Mrevlje, Štajer, Černelč, Koželj, Andoljšek, et al., 2011")</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b4">
            <label>4.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Li</surname> 
                     <given-names>PK</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Szeto</surname> 
                     <given-names>CC</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Piraino</surname> 
                     <given-names>B</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>de Arteaga</surname> 
                     <given-names>J</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Fan</surname> 
                     <given-names>S</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Figueiredo</surname> 
                     <given-names>AE</given-names>
                  </string-name>, <etal>et al.</etal>
               </person-group> 
               <article-title>ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment</article-title>. <source>Perit Dial Int</source>. <year>2016</year> 
               <month>Sep</month>;<volume>36</volume>(<issue>5</issue>):<fpage>481</fpage>–<lpage>508</lpage>. <pub-id pub-id-type="doi">10.3747/pdi.2016.00078</pub-id>
               <pub-id pub-id-type="pmid">27282851</pub-id>
               <issn>0896-8608</issn>
            </mixed-citation>
         </ref>
         <ref id="b5">
            <label>5.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Segal</surname> 
                     <given-names>JH</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Messana</surname> 
                     <given-names>JM</given-names>
                  </string-name>
               </person-group>. <article-title>Prevention of peritonitis in peritoneal dialysis</article-title>. <source>Semin Dial</source>. <year>2013</year> 
               <month>Jul-Aug</month>;<volume>26</volume>(<issue>4</issue>):<fpage>494</fpage>–<lpage>502</lpage>. <pub-id pub-id-type="doi">10.1111/sdi.12114</pub-id>
               <pub-id pub-id-type="pmid">23859192</pub-id>
               <issn>0894-0959</issn>
            </mixed-citation>
         </ref>
         <ref id="b6">
            <label>6.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Szeto</surname> 
                     <given-names>CC</given-names>
                  </string-name>
               </person-group>. <article-title>Peritonitis rates of the past thirty years: from improvement to stagnation</article-title>. <source>Perit Dial Int</source>. <year>2014</year> 
               <month>Mar-Apr</month>;<volume>34</volume>(<issue>2</issue>):<fpage>151</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.3747/pdi.2014.00007</pub-id>
               <pub-id pub-id-type="pmid">24676740</pub-id>
               <issn>0896-8608</issn>
            </mixed-citation>
         </ref>
         <ref id="b7">
            <label>7.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Khilji</surname> 
                     <given-names>MF</given-names>
                  </string-name>
               </person-group>. <article-title>Primary Peritonitis-A Forgotten Entity</article-title>. <source>European J Pediatr Surg Rep</source>. <year>2015</year> 
               <month>Jun</month>;<volume>3</volume>(<issue>1</issue>):<fpage>27</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">26171311</pub-id>
               <issn>2194-7619</issn>
            </mixed-citation>
         </ref>
         <ref id="b8">
            <label>8. </label>
            <mixed-citation publication-type="book-chapter" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Holzheimer</surname> 
                     <given-names>RG</given-names>
                  </string-name>
               </person-group>. <chapter-title>Management of secondary peritonitis</chapter-title>. In: <person-group person-group-type="editor">
                  <string-name name-style="western">
                     <surname>Holzheimer</surname> 
                     <given-names>RG</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Mannick</surname> 
                     <given-names>JA</given-names>
                  </string-name>, <role>editors</role>
               </person-group>. <source>Surgical Treatment: Evidence-Based and Problem-Oriented</source>. <publisher-loc>Munich</publisher-loc>: <publisher-name>Zuckschwerdt</publisher-name>; <year>2001</year>.</mixed-citation>
         </ref>
         <ref id="b9">
            <label>9.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Mishra</surname> 
                     <given-names>SP</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Tiwary</surname> 
                     <given-names>SK</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Mishra</surname> 
                     <given-names>M</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Gupta</surname> 
                     <given-names>SK</given-names>
                  </string-name>
               </person-group>. <article-title>An introduction of Tertiary Peritonitis</article-title>. <source>J Emerg Trauma Shock</source>. <year>2014</year> 
               <month>Apr</month>;<volume>7</volume>(<issue>2</issue>):<fpage>121</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.4103/0974-2700.130883</pub-id>
               <pub-id pub-id-type="pmid">24812458</pub-id>
               <issn>0974-2700</issn>
            </mixed-citation>
         </ref>
         <ref id="b10">
            <label>10.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Walker</surname> 
                     <given-names>A</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Bannister</surname> 
                     <given-names>K</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>George</surname> 
                     <given-names>C</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Mudge</surname> 
                     <given-names>D</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Yehia</surname> 
                     <given-names>M</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Lonergan</surname> 
                     <given-names>M</given-names>
                  </string-name>, <etal>et al.</etal>
               </person-group> 
               <article-title>KHA-CARI Guideline: peritonitis treatment and prophylaxis</article-title>. <source>Nephrology (Carlton)</source>. <year>2014</year> 
               <month>Feb</month>;<volume>19</volume>(<issue>2</issue>):<fpage>69</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1111/nep.12152</pub-id>
               <pub-id pub-id-type="pmid">23944845</pub-id>
               <issn>1320-5358</issn>
            </mixed-citation>
         </ref>
         <ref id="b11">
            <label>11.	</label>
            <mixed-citation publication-type="web-page" specific-use="unparsed">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Burkart</surname> 
                     <given-names>MD</given-names>
                  </string-name>
               </person-group>. <article-title>Microbiology and therapy of peritonitis in peritoneal dialysis.</article-title> Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc [cited 2018 May 15]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.uptodate.com">http://www.uptodate.com</ext-link>
            </mixed-citation>
         </ref>
         <ref id="b12">
            <label>12.	</label>
            <mixed-citation publication-type="web-page" specific-use="unparsed">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Burkart</surname> 
                     <given-names>MD</given-names>
                  </string-name>
               </person-group>. <article-title>Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis.</article-title> Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <ext-link ext-link-type="uri" xlink:href="http://www.uptodate.com">http://www.uptodate.com</ext-link> (dostopno 15. maja <year>2018</year>).<annotation>
                  <p content-type="warning">Reference 12 "Burkart, 2018" is similar to reference 11 and may be a duplicate. Please compare these references carefully.</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b13">
            <label>13.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Montravers</surname> 
                     <given-names>P</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Blot</surname> 
                     <given-names>S</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Dimopoulos</surname> 
                     <given-names>G</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Eckmann</surname> 
                     <given-names>C</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Eggimann</surname> 
                     <given-names>P</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Guirao</surname> 
                     <given-names>X</given-names>
                  </string-name>, <etal>et al.</etal>
               </person-group> 
               <article-title>Therapeutic management of peritonitis: a comprehensive guide for intensivists</article-title>. <source>Intensive Care Med</source>. <year>2016</year> 
               <month>Aug</month>;<volume>42</volume>(<issue>8</issue>):<fpage>1234</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1007/s00134-016-4307-6</pub-id>
               <pub-id pub-id-type="pmid">26984317</pub-id>
               <issn>0342-4642</issn>
            </mixed-citation>
         </ref>
         <ref id="b14">
            <label>14.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Cho</surname> 
                     <given-names>Y</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Johnson</surname> 
                     <given-names>DW</given-names>
                  </string-name>
               </person-group>. <article-title>Peritoneal dialysis-related peritonitis: towards improving evidence, practices, and outcomes</article-title>. <source>Am J Kidney Dis</source>. <year>2014</year> 
               <month>Aug</month>;<volume>64</volume>(<issue>2</issue>):<fpage>278</fpage>–<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1053/j.ajkd.2014.02.025</pub-id>
               <pub-id pub-id-type="pmid">24751170</pub-id>
               <issn>0272-6386</issn>
            </mixed-citation>
         </ref>
         <ref id="b15">
            <label>15.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Kendrick</surname> 
                     <given-names>J</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Teitelbaum</surname> 
                     <given-names>I</given-names>
                  </string-name>
               </person-group>. <article-title>Strategies for improving long-term survival in peritoneal dialysis patients</article-title>. <source>Clin J Am Soc Nephrol</source>. <year>2010</year> 
               <month>Jun</month>;<volume>5</volume>(<issue>6</issue>):<fpage>1123</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.2215/CJN.04300709</pub-id>
               <pub-id pub-id-type="pmid">20430945</pub-id>
               <issn>1555-9041</issn>
            </mixed-citation>
         </ref>
         <ref id="b16">
            <label>16.	</label>
            <mixed-citation publication-type="book-chapter" specific-use="unparsed">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Kovač</surname> 
                     <given-names>D</given-names>
                  </string-name>
               </person-group>. <chapter-title>Kako povečati program peritonealne dialize v Sloveniji.</chapter-title> In: 30-letnica kontinuirane peritonealne dialize v Sloveniji; 20. in 21. november 2014; Hotel Mons, Slovensko nefrološko društvo, Ljubljana, Slovenija. Ljubljana: UKC, KO za nefrologijo; <year>2014</year>.<annotation>
                  <p content-type="warning">Edifix Bibliographic Reference Processing failed to fully style this reference. Please check the copyediting. (Ref. 16 "Kovač, 2014")</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b17">
            <label>17.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Buturović-Ponikvar</surname> 
                     <given-names>J</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Gubenšek</surname> 
                     <given-names>J</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Arnol</surname> 
                     <given-names>M</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Adamlje</surname> 
                     <given-names>T</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Ceglar</surname> 
                     <given-names>Z</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Damevska</surname> 
                     <given-names>G</given-names>
                  </string-name>, <etal>et al.</etal>
               </person-group> 
               <article-title>Renal Replacement Therapy in Slovenia: Excerpts From 2013 Data</article-title>. <source>Ther Apher Dial</source>. <year>2016</year> 
               <month>Jun</month>;<volume>20</volume>(<issue>3</issue>):<fpage>223</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/1744-9987.12427</pub-id>
               <pub-id pub-id-type="pmid">27312905</pub-id>
               <issn>1744-9979</issn>
            </mixed-citation>
         </ref>
         <ref id="b18">
            <label>18.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Mehrotra</surname> 
                     <given-names>R</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Devuyst</surname> 
                     <given-names>O</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Davies</surname> 
                     <given-names>SJ</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Johnson</surname> 
                     <given-names>DW</given-names>
                  </string-name>
               </person-group>. <article-title>The Current State of Peritoneal Dialysis</article-title>. <source>J Am Soc Nephrol</source>. <year>2016</year> 
               <month>Nov</month>;<volume>27</volume>(<issue>11</issue>):<fpage>3238</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2016010112</pub-id>
               <pub-id pub-id-type="pmid">27339663</pub-id>
               <issn>1046-6673</issn>
            </mixed-citation>
         </ref>
         <ref id="b19">
            <label>19.	</label>
            <mixed-citation publication-type="book" specific-use="unparsed">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Tomažič</surname> 
                     <given-names>J</given-names>
                  </string-name>
               </person-group>. in Strle F. s sodelavci. Infekcijske bolezni. Ljubljana: Slovensko zdravniško društvo, Združenje za infektologijo; <year>2014/2015</year>. p. 375<annotation>
                  <p content-type="warning">Edifix Bibliographic Reference Processing failed to fully style this reference. Please check the copyediting. (Ref. 19 "Tomažič, 2014/2015")</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b20">
            <label>20.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Mlinšek</surname> 
                     <given-names>D</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Savicki</surname> 
                     <given-names>B</given-names>
                  </string-name>
               </person-group>. <article-title>Postopki pri zdravljenju peritonitisa kot zaplet kontinuirane peritonealne dialize. Ljubljana</article-title>. <source>Obzor Zdr N.</source> 
               <year>1994</year>;<volume>28</volume>:<fpage>109</fpage>–<lpage>11</lpage>.<annotation>
                  <p content-type="warning">Edifix does not recognize the journal "Obzor Zdr N.". If this is a valid journal title, please send this reference to journals@inera.com for addition to our journal database. (Ref. 20 "Mlinšek, Savicki, 1994")</p>
                  <p content-type="warning">Edifix has not found an issue number in the journal reference. Please check the volume/issue information. (Ref. 20 "Mlinšek, Savicki, 1994")</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b21">
            <label>21.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Akoh</surname> 
                     <given-names>JA</given-names>
                  </string-name>
               </person-group>. <article-title>Peritoneal dialysis associated infections: an update on diagnosis and management</article-title>. <source>World J Nephrol</source>. <year>2012</year> 
               <month>Aug</month>;<volume>1</volume>(<issue>4</issue>):<fpage>106</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.5527/wjn.v1.i4.106</pub-id>
               <pub-id pub-id-type="pmid">24175248</pub-id>
               <issn>2220-6124</issn>
            </mixed-citation>
         </ref>
         <ref id="b22">
            <label>22.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Okamoto</surname> 
                     <given-names>T</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Ikenoue</surname> 
                     <given-names>T</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Matsui</surname> 
                     <given-names>K</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Miyazaki</surname> 
                     <given-names>M</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Tsuzuku</surname> 
                     <given-names>Y</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Nishizawa</surname> 
                     <given-names>Y</given-names>
                  </string-name>, <etal>et al.</etal>
               </person-group> 
               <article-title>Free air on CT and the risk of peritonitis in peritoneal dialysis patients: a retrospective study</article-title>. <source>Ren Fail</source>. <year>2014</year> 
               <month>Nov</month>;<volume>36</volume>(<issue>10</issue>):<fpage>1492</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.3109/0886022X.2014.958953</pub-id>
               <pub-id pub-id-type="pmid">25211321</pub-id>
               <issn>0886-022X</issn>
            </mixed-citation>
         </ref>
         <ref id="b23">
            <label>23.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Temiz</surname> 
                     <given-names>G</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Sahin</surname> 
                     <given-names>G</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Mukerrem</surname> 
                     <given-names>G</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Ozkurt</surname> 
                     <given-names>S</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Degirmenci</surname> 
                     <given-names>NA</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Yalcin</surname> 
                     <given-names>AU</given-names>
                  </string-name>
               </person-group>. <article-title>Ultrasonographic evaluation of peritoneal membrane thickness and comparison with the effectiveness and duration of CAPD</article-title>. <source>Int Urol Nephrol</source>. <year>2013</year> 
               <month>Dec</month>;<volume>45</volume>(<issue>6</issue>):<fpage>1761</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1007/s11255-013-0504-1</pub-id>
               <pub-id pub-id-type="pmid">23884729</pub-id>
               <issn>0301-1623</issn>
            </mixed-citation>
         </ref>
         <ref id="b24">
            <label>24.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Barretti</surname> 
                     <given-names>P</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Doles</surname> 
                     <given-names>JV</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Pinotti</surname> 
                     <given-names>DG</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>El Dib</surname> 
                     <given-names>R</given-names>
                  </string-name>
               </person-group>. <article-title>Efficacy of antibiotic therapy for peritoneal dialysis-associated peritonitis: a proportional meta-analysis</article-title>. <source>BMC Infect Dis</source>. <year>2014</year> 
               <month>Aug</month>;<volume>14</volume>(<issue>1</issue>):<fpage>445</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2334-14-445</pub-id>
               <pub-id pub-id-type="pmid">25135487</pub-id>
               <issn>1471-2334</issn>
            </mixed-citation>
         </ref>
         <ref id="b25">
            <label>25.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Chow</surname> 
                     <given-names>KM</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Szeto</surname> 
                     <given-names>CC</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Cheung</surname> 
                     <given-names>KK</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Leung</surname> 
                     <given-names>CB</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Wong</surname> 
                     <given-names>SS</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Law</surname> 
                     <given-names>MC</given-names>
                  </string-name>, <etal>et al.</etal>
               </person-group> 
               <article-title>Predictive value of dialysate cell counts in peritonitis complicating peritoneal dialysis</article-title>. <source>Clin J Am Soc Nephrol</source>. <year>2006</year> 
               <month>Jul</month>;<volume>1</volume>(<issue>4</issue>):<fpage>768</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.2215/CJN.01010306</pub-id>
               <pub-id pub-id-type="pmid">17699285</pub-id>
               <issn>1555-9041</issn>
            </mixed-citation>
         </ref>
         <ref id="b26">
            <label>26.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Bender</surname> 
                     <given-names>FH</given-names>
                  </string-name>
               </person-group>. <article-title>Avoiding harm in peritoneal dialysis patients</article-title>. <source>Adv Chronic Kidney Dis</source>. <year>2012</year> 
               <month>May</month>;<volume>19</volume>(<issue>3</issue>):<fpage>171</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1053/j.ackd.2012.04.002</pub-id>
               <pub-id pub-id-type="pmid">22578677</pub-id>
               <issn>1548-5595</issn>
            </mixed-citation>
         </ref>
         <ref id="b27">
            <label>27.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Janež</surname> 
                     <given-names>J</given-names>
                  </string-name>
               </person-group>. <article-title>Laparoskopska vstavitev katetra za peritonealno dializo</article-title>. <source>Med Razgl</source>. <year>2017</year>;<volume>56</volume>(<issue>4</issue>):<fpage>517</fpage>–<lpage>24</lpage>.<issn>0025-8121</issn>
            </mixed-citation>
         </ref>
         <ref id="b28">
            <label>28.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Pintar</surname> 
                     <given-names>T</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Trotovšek</surname> 
                     <given-names>B</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Beović</surname> 
                     <given-names>B</given-names>
                  </string-name>
               </person-group>. <article-title>Smernice za profilaktično uporabo antibiotikov v abdominalni kirurgiji za odrasle</article-title>. <source>Zdrav Vestn</source>. <year>2014</year>;<volume>83</volume>:<fpage>651</fpage>–<lpage>60</lpage>.<issn>0350-0063</issn>
               <annotation>
                  <p content-type="warning">Edifix has not found an issue number in the journal reference. Please check the volume/issue information. (Ref. 28 "Pintar, Trotovšek, Beović, 2014")</p>
               </annotation>
            </mixed-citation>
         </ref>
         <ref id="b29">
            <label>29.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Gadallah</surname> 
                     <given-names>MF</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Ramdeen</surname> 
                     <given-names>G</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Mignone</surname> 
                     <given-names>J</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Patel</surname> 
                     <given-names>D</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Mitchell</surname> 
                     <given-names>L</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Tatro</surname> 
                     <given-names>S</given-names>
                  </string-name>
               </person-group>. <article-title>Role of preoperative antibiotic prophylaxis in preventing postoperative peritonitis in newly placed peritoneal dialysis catheters</article-title>. <source>Am J Kidney Dis</source>. <year>2000</year> 
               <month>Nov</month>;<volume>36</volume>(<issue>5</issue>):<fpage>1014</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1053/ajkd.2000.19104</pub-id>
               <pub-id pub-id-type="pmid">11054359</pub-id>
               <issn>0272-6386</issn>
            </mixed-citation>
         </ref>
         <ref id="b30">
            <label>30.	</label>
            <mixed-citation publication-type="journal" specific-use="restruct">
               <person-group person-group-type="author">
                  <string-name name-style="western">
                     <surname>Velloso</surname> 
                     <given-names>MS</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Otoni</surname> 
                     <given-names>A</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>de Paula Sabino</surname> 
                     <given-names>A</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>de Castro</surname> 
                     <given-names>WV</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Pinto</surname> 
                     <given-names>SW</given-names>
                  </string-name>, <string-name name-style="western">
                     <surname>Marinho</surname> 
                     <given-names>MA</given-names>
                  </string-name>, <etal>et al.</etal>
               </person-group> 
               <article-title>Peritoneal dialysis and inflammation</article-title>. <source>Clin Chim Acta</source>. <year>2014</year> 
               <month>Mar</month>;<volume>430</volume>:<fpage>109</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.cca.2013.12.003</pub-id>
               <pub-id pub-id-type="pmid">24333488</pub-id>
               <issn>0009-8981</issn>
               <annotation>
                  <p content-type="warning">Edifix has not found an issue number in the journal reference. Please check the volume/issue information. (Ref. 30 "Velloso, Otoni, 2014")</p>
               </annotation>
            </mixed-citation>
         </ref>
      </ref-list>
   </back>
   <sub-article id="article-en" xml:lang="en" article-type="other">
      <front>
         <journal-meta>
            <journal-id journal-id-type="publisher-id">Zdrav Vestn</journal-id>
            <journal-id journal-id-type="nlm-ta">Zdrav Vestn</journal-id>
            <journal-id journal-id-type="doi">Zdrav Vestn</journal-id>
            <journal-title-group>
               <journal-title>Slovenian Medical Journal</journal-title>
               <!--<trans-title-group xml:lang="sl"><trans-title>Zdravniški vestnik</trans-title></trans-title-group>-->
               <abbrev-journal-title>Zdrav Vestn</abbrev-journal-title>
            </journal-title-group>
            <issn publication-format="ppub" pub-type="ppub">1318-0347</issn>
            <issn publication-format="epub" pub-type="epub">1581-0224</issn>
            <issn-l>0350-0063</issn-l>
            <publisher>
               <publisher-name xml:lang="sl">Slovensko zdravniško društvo</publisher-name>
               <publisher-name xml:lang="en">Slovenian Medical Association</publisher-name>
               <publisher-loc xml:lang="sl">Ljubljana, Slovenia</publisher-loc>
            </publisher>
         </journal-meta>
         <article-meta>
            <article-id pub-id-type="doi">10.6016/ZdravVestn.2844</article-id>
            <article-id pub-id-type="publisher-id">2844</article-id>
            <article-categories>
               <subj-group subj-group-type="discipline" xml:lang="en">
                  <subject>Medicine and health sciences</subject>
                  <subj-group>
                     <subject>Metabolic and hormonal disorders</subject>
                  </subj-group>
               </subj-group>
               <subj-group subj-group-type="article-type" xml:lang="en">
                  <subject>Review article</subject>
               </subj-group>
               <subj-group subj-group-type="heading" xml:lang="en">
                  <subject>Metabolic and hormonal disorders</subject>
               </subj-group>
            </article-categories>
            <title-group>
               <article-title xml:lang="en">Peritoneal dialysis-associated peritonitis</article-title>
               <alt-title alt-title-type="running-head" xml:lang="en">Peritoneal dialysis-associated peritonitis</alt-title>
            </title-group>
            <contrib-group>
               <contrib contrib-type="author" xlink:type="simple">
                  <name name-style="western">
                     <surname>Janež</surname>
                     <given-names>Jurij</given-names>
                  </name>
                  <xref ref-type="aff" rid="en-aff1">1</xref>
                  <xref ref-type="corresp" rid="en-corr"/>
               </contrib>
               <contrib contrib-type="author" xlink:type="simple">
                  <name name-style="western">
                     <surname>Čebron</surname>
                     <given-names>Žan</given-names>
                  </name>
                  <xref ref-type="aff" rid="en-aff1">1</xref>
               </contrib>
            </contrib-group>
            <aff id="en-aff1" xml:lang="en">
               <label>1</label>
               <institution>Department of Abdominal Surgery, Division of Surgery, University Medical Centre Ljubljana, Ljubljana, Slovenia</institution>
            </aff>
            <author-notes>
               <fn fn-type="conflict" xml:lang="en">
                  <p>The authors have declared that no competing interests exist.</p>
               </fn>
               <fn fn-type="conflict" xml:lang="sl">
                  <p>Avtorji so izjavili, da ne obstajajo nobeni konkurenčni interesi.</p>
               </fn>
               <corresp id="en-corr">Jurij Janež, e-mail: <email xlink:type="simple"/>
               </corresp>
            </author-notes>
            <pub-date pub-type="ppub">
               <month>2</month>
               <year>2019</year>
            </pub-date>
            <pub-date pub-type="epub">
               <month>2</month>
               <year>2019</year>
            </pub-date>
            <volume>88</volume>
            <issue>1–2</issue>
            <fpage>39</fpage>
            <lpage>49</lpage>
            <history>
               <date date-type="received">
                  <day>26</day>
                  <month>5</month>
                  <year>2018</year>
               </date>
               <date date-type="accepted">
                  <day>10</day>
                  <month>2</month>
                  <year>2019</year>
               </date>
            </history>
            <permissions>
               <copyright-statement xml:lang="en">Copyright © 2019, Slovenian Medical Association (SZD)</copyright-statement>
               <copyright-statement xml:lang="sl">© 2019, Slovensko zdravniško društvo (SZD)</copyright-statement>
               <copyright-year>2019</copyright-year>
               <copyright-holder xml:lang="en">Slovenian Medical Association (SZD)</copyright-holder>
               <copyright-holder xml:lang="sl">Slovensko zdravniško društvo (SZD)</copyright-holder>
               <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                        xlink:type="simple"
                        xml:lang="en">
                  <license-p>This is an open access article distributed under the terms of the
          <ext-link ext-link-type="uri"
                               xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                               xlink:type="simple">Creative Commons Attribution-NonCommercial
            License</ext-link>, which permits unrestricted use, distribution, and
          reproduction in any medium, provided the original author and source are
          credited and only for non-commercial purposes. </license-p>
               </license>
               <license xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                        xlink:type="simple"
                        xml:lang="sl">
                  <license-p>To je članek z odprtim dostopom, ki ga lahko uporabite pod pogoji iz
          <ext-link ext-link-type="uri"
                               xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"
                               xlink:type="simple">Creative Commons Priznanje avtorstva-Nekomercialno
            licence</ext-link>. ki dovoljuje distribucijo, predelavo ali
          prilagoditev, ter gradijo na njem, v nekomercialne namene, z navedbo avtorja
          in izvirnega dela.</license-p>
               </license>
            </permissions>
            <abstract xml:lang="en">
               <title>Abstract</title>
               <p>Peritoneal dialysis is used worldwide as a treatment for end-stage kidney failure. Globally, it accounts for about 11 % of all therapeutic dialysis interventions, with over 200.000 patients currently undergoing the procedure in more than 130 countries. In Slovenia, however, the percentage of patients treated by peritoneal dialysis has fallen due to the rise in renal transplantation services and the number of transplanted patients with functioning kidney graft. In 2013, patients receiving peritoneal dialysis in Slovenia accounted for only 2.5 % (52 patients) of the total number treated by renal replacement therapy (2077 patients).</p>
               <p>A potential complication of peritoneal dialysis is peritonitis. Although in general, peritonitis-related mortality has declined significantly in the last decade (with less than 5 % of peritonitis episodes resulting in death) possibly due to improved preventive measures, peritonitis still remains a direct or major contributing cause of mortality in approximately 16 % of peritoneal dialysis patients.</p>
               <p>In these patients, the time frame between the onset of peritonitis and the commencement of treatment critically determines the course and outcome of the disease. Peritonitis patients require urgent care, and therapeutic interventions may include conservative and/or surgical treatment protocols.</p>
               <p>Meanwhile, it is important to emphasize that prevention of peritoneal dialysis-associated peritonitis is as important as early diagnosis and timely treatment.</p>
            </abstract>
            <kwd-group xml:lang="en">
               <kwd>peritonitis</kwd>
               <kwd>peritoneal dialysis</kwd>
               <kwd>treatment</kwd>
               <kwd>prevention</kwd>
            </kwd-group>
            <custom-meta-group>
               <custom-meta>
                  <meta-name>TotalReferences</meta-name>
                  <meta-value>30</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>ReferencesParsed</meta-name>
                  <meta-value>26</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>ReferencesBillable</meta-name>
                  <meta-value>24</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>LinkServices</meta-name>
                  <meta-value>pubmed-crossref</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>ReferencesLinked</meta-name>
                  <meta-value>19</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>ReferencesLinkedDOI</meta-name>
                  <meta-value>18</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>ReferencesLinkedPMID</meta-name>
                  <meta-value>19</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>JournalReferences</meta-name>
                  <meta-value>22</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>BookReferences</meta-name>
                  <meta-value>3</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>BookChapterReferences</meta-name>
                  <meta-value>3</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>ConferenceReferences</meta-name>
                  <meta-value>0</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>ElectronicReferences</meta-name>
                  <meta-value>2</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>DissertationReferences</meta-name>
                  <meta-value>0</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>LegalReferences</meta-name>
                  <meta-value>0</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>StandardReferences</meta-name>
                  <meta-value>0</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>OtherReferences</meta-name>
                  <meta-value>0</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>UnknownReferences</meta-name>
                  <meta-value>1</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>ReferencesSemiParsed</meta-name>
                  <meta-value>0</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>ReferencesBookUnparsed</meta-name>
                  <meta-value>3</meta-value>
               </custom-meta>
               <custom-meta>
                  <meta-name>EditorialStyle</meta-name>
                  <meta-value>ICMJE-WHO</meta-value>
               </custom-meta>
            </custom-meta-group>
         </article-meta>
      </front>
      <body>
         <sec id="en-s1" sec-type="Introduction">
            <label>1</label>
            <title>Introduction</title>
            <p>Peritonitis is acute inflammation of visceral and parietal layers of peritoneum, which can severely affect the patient and be even life-threatening. Due to the high concentration of bacteria in the gastrointestinal tract, and large peritoneum surface, it often leads to sepsis (<xref ref-type="bibr" rid="en-b1">1</xref>,<xref ref-type="bibr" rid="en-b2">2</xref>). Ever since peritoneal dialysis (PD) was introduced after 1960, peritonitis has been a serious complication that damages the peritoneal membrane and causes structural and functional changes. It is the most common cause of hospital admission and the removal of peritoneal dialysis catheter, and the reason for discontinuing peritoneal dialysis in 30–80% of cases. In Slovenia, peritonitis incidence is estimated to stand at about 0.33 episode per patient-year of treatment (one episode every 36 months of the patient’s treatment) (<xref ref-type="bibr" rid="en-b3">3</xref>-<xref ref-type="bibr" rid="en-b6">6</xref>).</p>
         </sec>
         <sec id="en-s2" sec-type="Peritonitis">
            <label>2</label>
            <title>Peritonitis</title>
            <p>Peritonitis is the inflammation of visceral and parietal layers of peritoneum due to various reasons. Based on the cause and mechanism of formation, peritonitis can be classified as primary, secondary or tertiary (<xref ref-type="bibr" rid="en-b1">1</xref>,<xref ref-type="bibr" rid="en-b2">2</xref>). Primary peritonitis, which represents about 10% of all peritonitis cases, is rare inflammation of peritoneum with no pathological changes proven in the abdomen. It most frequently affects children, patients with cirrhosis and ascites, people with nephrotic syndrome and patients with with congestive heart failure (<xref ref-type="bibr" rid="en-b2">2</xref>,<xref ref-type="bibr" rid="en-b7">7</xref>). Secondary peritonitis, which is more common (about 80% of the cases), is infection caused by an injury or inflammation in the abdominal cavity. Secondary peritonitis most frequently occurs in patients with peptic ulcer disease, acute appendicitis, acute cholecystitis, and diverticulosis (<xref ref-type="bibr" rid="en-b2">2</xref>,<xref ref-type="bibr" rid="en-b8">8</xref>), and also occurs as a complication in PD patients. The etiopathogenesis of peritonitis caused by PD is described below. Tertiary peritonitis (approximately 10% of the cases) is the infection of peritoneum with low virulent bacteria or fungi, which persists even though the abdominal origin of sepsis has been cured. It is most frequent in immunocompromised patients (<xref ref-type="bibr" rid="en-b1">1</xref>,<xref ref-type="bibr" rid="en-b8">8</xref>,<xref ref-type="bibr" rid="en-b9">9</xref>).</p>
            <p>Patients with peritonitis require conservative and/or surgical treatment. Peritonitis is treated by eliminating the origin of infection, rinsing the abdominal cavity with a 0.9% NaCl solution, and introducing first empiric and then targeted antibiotic therapy. Post-operative intensive care with fluid infusions, electrolyte replacement, correction of metabolic disorders and vital organs support can contribute critically to the successful outcome of the treatment. It is vital to suspect peritonitis as soon as possible, confirm the diagnosis and immediately start the treatment. The time between the onset of peritonitis and the commencement of treatment critically determines the course and outcome of the disease (<xref ref-type="bibr" rid="en-b1">1</xref>,<xref ref-type="bibr" rid="en-b2">2</xref>,<xref ref-type="bibr" rid="en-b10">10</xref>-<xref ref-type="bibr" rid="en-b13">13</xref>).</p>
         </sec>
         <sec id="en-s3" sec-type="Epidemiology">
            <label>3</label>
            <title>Epidemiology</title>
            <p>Peritoneal dialysis is used worldwide as a treatment for end-stage kidney failure. Globally, it accounts for about 11% of all therapeutic dialysis interventions, with over 200,000 patients currently undergoing the procedure in more than 130 countries (<xref ref-type="bibr" rid="en-b14">14</xref>). In USA, their number stands at around 26,000 (<xref ref-type="bibr" rid="en-b15">15</xref>). The prevalence and share of patients treated with PD in Slovenia have decreased over the past decade, dropping considerably under the global average of 11% (<xref ref-type="bibr" rid="en-b16">16</xref>). In 2013, only 52 patients (2.5%) of the total 2077 patients treated by renal replacement therapy were receiving PD in Slovenia. The percentage of patients treated by PD has fallen primarily due to the increasing share of patients patients with a functioning kidney graft (32.5% of all patients) (<xref ref-type="bibr" rid="en-b17">17</xref>).</p>
            <p>The incidence of peritonitis in the first years after introducing PD was very high, it however dropped significantly after several preventive measures were introduced. In the USA, the incidence of peritonitis in PD patients in the 1980–1990 period was 1.1–1.3 episode per patient-year of treatment, while recent studies have reported the incidence of 0.4 episode per patient-year of treatment (<xref ref-type="bibr" rid="en-b4">4</xref>).</p>
            <p>Although the incidence of peritonitis has been decreasing in the past years, the data differ greatly between countries, as well centres within a country, with the reported incidence ranging from 0.06 to 1.66 episode per patient-year. The main reasons for such variation in incidence most probably lie in individual centre’s failure to comply with recommendations for preventing peritonitis, differences in patient population, and inconsistently collected data. The International Society for Peritoneal Dialysis (ISPD) believes that the incidence of peritonitis should not exceed 0.5 episode per patient-year of treatment in any of the centres. In Slovenia, peritonitis incidence is estimated to stand at about 0.33 episode per patient-year of treatment (one episode every 36 months of the patient’s treatment) (<xref ref-type="bibr" rid="en-b2">2</xref>-<xref ref-type="bibr" rid="en-b4">4</xref>,<xref ref-type="bibr" rid="en-b6">6</xref>,<xref ref-type="bibr" rid="en-b14">14</xref>,<xref ref-type="bibr" rid="en-b15">15</xref>,<xref ref-type="bibr" rid="en-b18">18</xref>).</p>
            <p>To guarantee the quality of collected data, which can then be compared between institutions to assess the centres’ quality of work, ISPD issued the following recommendations for recording peritonitis incidence in PD. Every centre performing PD should record annual incidence of peritonitis. It also recommends recording whether peritonitis occurred already in the hospital soon after placing the peritoneal dialysis catheter, or only after patients started home PD. When designing local recommendations for empiric antimicrobial therapy, data on the infecting organisms and their antimicrobial susceptibilities are essential. It is also recommended to record the number of patients who did not experience a peritonitis episode in the past year, and the number of deaths associated with peritonitis (deaths during hospitalization for a peritonitis episode or within 4 weeks of a peritonitis episode) (<xref ref-type="bibr" rid="en-b4">4</xref>).</p>
         </sec>
         <sec id="en-s4" sec-type="Etiopathogenesis">
            <label>4</label>
            <title>Etiopathogenesis</title>
            <p>There are several possible infection pathways:</p>
            <list>
               <list-item>
                  <label>•</label>
                  <p>intraluminal – the infection occurs through the peritoneal dialysis catheter following a contamination during bag exchange, or due to bacteria in the dialysis solution;</p>
               </list-item>
               <list-item>
                  <label>•</label>
                  <p>periluminal – the infection occurs alongside the catheter though the abdominal wall;</p>
               </list-item>
               <list-item>
                  <label>•</label>
                  <p>transmural – the infection occurs due to the translocation of enteric bacteria;</p>
               </list-item>
               <list-item>
                  <label>•</label>
                  <p>ascending – the infection occurs, if the vagina and the peritoneal cavity are linked through fallopian tubes or fistulas;</p>
               </list-item>
               <list-item>
                  <label>•</label>
                  <p>hematogenous.</p>
               </list-item>
            </list>
            <p>Most infections occurs through the intraluminal route. The periluminal pathway is a less common cause of infection due to the advancements and improvements in inserting dialysis catheters, as well as the use of double-cuff catheters that prevent the bacterial invasion to the peritoneal cavity. Other infection pathways are even less common (<xref ref-type="bibr" rid="en-b3">3</xref>,<xref ref-type="bibr" rid="en-b19">19</xref>,<xref ref-type="bibr" rid="en-b20">20</xref>).</p>
            <p>Globally, some 75% of cases are cause by gram-positive bacteria, with the most common causes being <italic toggle="yes">S. epidermidis</italic> (30–50% of all infections) and <italic toggle="yes">S. aureus</italic>, which are normally present on skin and can enter the abdominal cavity through the intraluminal pathway due to unsterile manipulation of catheter junctions. Other common causes are coagulase-negative staphylococci<italic toggle="yes">, E. coli</italic>, <italic toggle="yes">P. aeruginosa</italic> and fungi (especially <italic toggle="yes">Candida spp.</italic>) (<xref ref-type="bibr" rid="en-b2">2</xref>,<xref ref-type="bibr" rid="en-b3">3</xref>,<xref ref-type="bibr" rid="en-b19">19</xref>). Etiological data vary somewhat depending on the geographic location, e.g., in India peritonitis is more frequently caused by infection with gram-negative bacteria than with gram-positive bacteria, which negatively impacts treatment outcomes. There are no significant differences in the causes of peritonitis occurring in hospitals or at home (<xref ref-type="bibr" rid="en-b19">19</xref>,<xref ref-type="bibr" rid="en-b21">21</xref>).</p>
         </sec>
         <sec id="en-s5" sec-type="Clinical picture">
            <label>5</label>
            <title>Clinical picture</title>
            <p>Peritonitis is a common complication in PD. The most significant symptom of peritonitis is diffuse abdominal pain, and its most significant sign is cloudy dialysate (<xref ref-type="bibr" rid="en-b12">12</xref>,<xref ref-type="bibr" rid="en-b18">18</xref>). Cloudy dialysate is almost always a sign of infectious peritonitis, as other causes are extremely rare (e.g. chemical peritonitis, calcium channel antagonists, malignant disease, hemoperitoneum, etc.) (<xref ref-type="bibr" rid="en-b4">4</xref>). Severe peritonitis can also be accompanied by other symptoms and signs, such as elevated body temperature, nausea, vomiting, diarrhea, and poor dialysate outflow (<xref ref-type="bibr" rid="en-b3">3</xref>).</p>
         </sec>
         <sec id="en-s6" sec-type="Diagnosis">
            <label>6</label>
            <title>Diagnosis</title>
            <p>To confirm a peritonitis diagnosis, two of the following three criteria must be met:</p>
            <list>
               <list-item>
                  <label>1.</label>
                  <p>presence of clinical signs (e.g. abdominal tenderness or pain);</p>
               </list-item>
               <list-item>
                  <label>2.</label>
                  <p>cloudy peritoneal effluent with leukocyte count over 0.1 × 10<sup>9</sup>/L, more than 50% of which are neutrophils;</p>
               </list-item>
               <list-item>
                  <label>3.</label>
                  <p>microbes proved in the peritoneal effluent (<xref ref-type="bibr" rid="en-b3">3</xref>,<xref ref-type="bibr" rid="en-b4">4</xref>).</p>
               </list-item>
            </list>
            <p>To quickly determine whether peritonitis is caused by gram-positive or -negative bacteria, we may carry out gram staining of the effluent; however, the method has very low sensitivity, and only detects 10–40% of infected samples (<xref ref-type="bibr" rid="en-b2">2</xref>). Peritonitis should also be included in the differential diagnosis of a PD patient presenting with abdominal pain, even if the effluent is clear (<xref ref-type="bibr" rid="en-b4">4</xref>).</p>
            <p>Imaging tests are not really relevant in determining the diagnosis, they are however very helpful in eliminating other potential causes of peritonitis that are possible based on the patient’s clinical picture (<xref ref-type="bibr" rid="en-b11">11</xref>,<xref ref-type="bibr" rid="en-b12">12</xref>). If imaging tests show free air in PD patient’s abdomen, this is an independent risk factor for peritonitis, so the above listed tests must be carried out if the effluent is clear or cloudy to confirm or exclude peritonitis (<xref ref-type="bibr" rid="en-b22">22</xref>). The peritoneal membrane thickness, which affects the effectiveness of PD, can be evaluated using an ultrasound scan instead of invasive methods (<xref ref-type="bibr" rid="en-b23">23</xref>).</p>
         </sec>
         <sec id="en-s7" sec-type="Treatment">
            <label>7</label>
            <title>Treatment</title>
            <p>When the probability of peritonitis in PD patients is very high or confirmed, we must examine the catheter exit site and determine whether there are any signs of inflammation. We then take an effluent sample and send it to testing. We should not delay, but immediately start empiric antibiotic therapy, since the postponement of treatment may critically affect the course and outcome of the peritonitis episode. ISPD recommends discontinuing PD for at least 6–48 hours after administering the first dose of the antimicrobial medicine. The opinions on this are split, since discontinuing PD means that the patient will require hemodialysis, which comes with its own set of risks and complications. Some authors thus recommend not to discontinue PD, unless the peritoneal catheter must be removed. For every patient we must asses whether they require additional treatment with analgesics, intraperitoneal heparin or antifungal prophylaxis. Before the discharge, the patient must be taught how to administer intraperitoneal medicine, and given regular follow-up appointments. It is reasonable to check whether PD is performed correctly, and to point out any potential mistakes to the patient. Initial management of peritonitis is presented in <xref ref-type="fig" rid="en-fig1">Figure 1</xref> (<xref ref-type="bibr" rid="en-b4">4</xref>).</p>
            <fig position="anchor" id="en-fig1" orientation="portrait">
               <label>Figure 1:</label>
               <caption>
                  <p> Initial treatment of peritonitis; IP – intraperitoneal; modified from ISPD guidelines (<xref ref-type="bibr" rid="en-b4">4</xref>).</p>
               </caption>
               <p>
                  <graphic xlink:href="2844-en-web-resources/image/zdravvestn-2844-en-01.png"
                           position="float"
                           orientation="portrait"/>
               </p>
            </fig>
            <sec id="en-s7.1" sec-type="Antibiotic selection and dosage">
               <label>7.1</label>
               <title>Antibiotic selection and dosage</title>
               <p>The initial empiric therapy should cover both gram-positive and gram-negative organisms. ISPD recommends covering gram-positive organisms by vancomycin or a first generation cephalosporin (e.g. cefazolin), and gram-negative organisms by a third-generation cephalosporin (e.g. cefepime, ceftazidime) or an aminoglycoside (e.g. gentamicin). The local spectrum of antibiotic resistance and the experience of the dialysis centre prevail over ISPD recommendations. In Slovenia, best outcomes have been recorded for intraperitoneal therapy with cefazolin and gentamicin (see Algorithm 1). After receiving the bacteria culture and antimicrobial susceptibility testing results, we adjust the treatment if necessary. We successfully cure around 75% peritonitis cases with only antimicrobial therapy and without any other measures. The success of antimicrobial therapy without catheter removal largely depends on the organism causing the infection, and is as follows: coagulase-negative staphylococci – 90%, <italic toggle="yes">S. aureus</italic> – 66%, gram-negative bacteria – 56% and fungi – 0%. If the patient’s clinical status does not improve, and the effluent does not clear up in five days, the peritoneal catheter should be removed. In some cases we should not wait five days before removing the catheter; indications for removing the peritoneal catheter are described below. If the patient is at risk, is showing signs of sepsis and/or signs of infection of the catheter exit site, a systemic antibiotic should be administered intravenously, empirically selecting vancomycin and ceftazidime, or an antibiotic based on the causes and antimicrobial susceptibilities. Recommended doses for intraperitoneal delivery of commonly used antibiotics are presented in <xref ref-type="table" rid="en-table1">Table 1</xref> (<xref ref-type="bibr" rid="en-b2">2</xref>-<xref ref-type="bibr" rid="en-b4">4</xref>,<xref ref-type="bibr" rid="en-b19">19</xref>,<xref ref-type="bibr" rid="en-b24">24</xref>).</p>
               <table-wrap position="anchor" id="en-table1" orientation="portrait">
                  <label>Table 1:</label>
                  <caption>
                     <p> Dosing of antibiotics commonly used for the treatment of peritonitis in PD patients, modified from ISPD guidelines (<xref ref-type="bibr" rid="en-b4">4</xref>). LD – loading dose, MD – maintenance dose</p>
                  </caption>
                  <table>
                     <colgroup span="1">
                        <col span="1"/>
                        <col span="1"/>
                        <col span="1"/>
                     </colgroup>
                     <thead>
                        <tr>
                           <th rowspan="1" colspan="1">Antibiotic</th>
                           <th rowspan="1" colspan="1">Intermittent (1 exchange)</th>
                           <th rowspan="1" colspan="1">Continuous (all exchanges)</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td rowspan="1" colspan="1">Gentamicin</td>
                           <td rowspan="1" colspan="1">0.6 mg/kg daily</td>
                           <td rowspan="1" colspan="1">LD 25 mg/L, MD 12 mg/L</td>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">Amikacin</td>
                           <td rowspan="1" colspan="1">2 mg/kg daily</td>
                           <td rowspan="1" colspan="1">LD 8 mg/L, MD 4 mg/L</td>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">Cefazolin</td>
                           <td rowspan="1" colspan="1">15–20 mg/kg daily</td>
                           <td rowspan="1" colspan="1">LD 500 mg/L, MD 125 mg/L</td>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">Ceftriaxone</td>
                           <td rowspan="1" colspan="1">1,000 mg daily</td>
                           <td rowspan="1" colspan="1">no data</td>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">Cefotaxime</td>
                           <td rowspan="1" colspan="1">500–1,000 mg daily</td>
                           <td rowspan="1" colspan="1">no data</td>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">Ceftazidime</td>
                           <td rowspan="1" colspan="1">1,000–1,500 mg daily</td>
                           <td rowspan="1" colspan="1">LD 500 mg/L, MD 125 mg/L</td>
                        </tr>
                        <tr>
                           <td rowspan="1" colspan="1">Vancomycin</td>
                           <td rowspan="1" colspan="1">15–30 mg/kg every 5–7 days</td>
                           <td rowspan="1" colspan="1">LD 30 mg/kg, MD 1.5 mg/kg/bag</td>
                        </tr>
                     </tbody>
                  </table>
               </table-wrap>
            </sec>
            <sec id="en-s7.2" sec-type="Treatment duration">
               <label>7.2</label>
               <title>Treatment duration</title>
               <p>The duration of treatment depends on the organism causing the infection. For recommended duration of treatment for individual organisms see <table-wrap position="float" id="en-table2" orientation="portrait">
                     <label>Table 2:</label>
                     <caption>
                        <p> The duration and specifics of treatment based on the organism causing peritonitis, modified from ISPD guidelines (<xref ref-type="bibr" rid="en-b4">4</xref>). </p>
                     </caption>
                     <table>
                        <colgroup span="1">
                           <col span="1"/>
                           <col span="1"/>
                        </colgroup>
                        <thead>
                           <tr>
                              <th rowspan="1" colspan="1">Organism</th>
                              <th rowspan="1" colspan="1">Recommendations</th>
                           </tr>
                        </thead>
                        <tbody>
                           <tr>
                              <td rowspan="1" colspan="1">Coagulase-negative staphylococci</td>
                              <td rowspan="1" colspan="1">
                                 <p>Treatment with IP cephalosporins or vancomycin, according to local antimicrobial susceptibility.</p>
                                 <p>Duration of treatment: 2 weeks.</p>
                              </td>
                           </tr>
                           <tr>
                              <td rowspan="1" colspan="1">Enterococcus spp.</td>
                              <td rowspan="1" colspan="1">
                                 <p>Treatment with IP vancomycin. IP aminoglycosides for severe peritonitis.</p>
                                 <p>Duration of treatment: 3 weeks.</p>
                                 <p>*Exception: vancomycin-resistant Enterococcus (VRE) – treatment with IP ampicillin. If the organism is ampicillin-resistant, therapy based on antimicrobial susceptibilities (e.g. linezolid, teicoplanin, etc.).</p>
                              </td>
                           </tr>
                           <tr>
                              <td rowspan="1" colspan="1">Streptococcus spp.</td>
                              <td rowspan="1" colspan="1">
                                 <p>Treatment with IP ampicillin.</p>
                                 <p>Duration of treatment: 2 weeks.</p>
                              </td>
                           </tr>
                           <tr>
                              <td rowspan="1" colspan="1">S. aureus</td>
                              <td rowspan="1" colspan="1">
                                 <p>Treatment with locally effective antibiotics.</p>
                                 <p>Duration of treatment: 3 weeks.</p>
                              </td>
                           </tr>
                           <tr>
                              <td rowspan="1" colspan="1">Corynebacterium spp.</td>
                              <td rowspan="1" colspan="1">
                                 <p>Treatment with locally effective antibiotics.</p>
                                 <p>Duration of treatment: 3 weeks.</p>
                              </td>
                           </tr>
                           <tr>
                              <td rowspan="1" colspan="1">Pseudomonas spp.</td>
                              <td rowspan="1" colspan="1">
                                 <p>Treatment with 2 antibiotics with different mechanisms of action (e.g. IP gentamicin or oral ciprofloxacin with IP ceftazidime or cefepime).</p>
                                 <p>Duration of treatment: 3 weeks.</p>
                                 <p>In the event of an exit-site infection, the catheter should be removed.</p>
                              </td>
                           </tr>
                           <tr>
                              <td rowspan="1" colspan="1">Other gram-negative bacteria</td>
                              <td rowspan="1" colspan="1">
                                 <p>Treatment with locally effective antibiotics.</p>
                                 <p>Duration of treatment: 3 weeks.</p>
                              </td>
                           </tr>
                           <tr>
                              <td rowspan="1" colspan="1">Polymicrobial peritonitis</td>
                              <td rowspan="1" colspan="1">
                                 <p>Enteric organisms</p>
                                 <p>If there is no response to the initial empiric therapy, we conduct diagnostic imaging (abdominal ultrasound, CT scans) and consult with a surgeon.</p>
                                 <p>Treatment with metronidazole, IP vancomycin and either IP aminoglycoside or IP ceftazidime.</p>
                                 <p>Duration of treatment: at least 3 weeks.</p>
                                 <p>Multiple gram-positive organisms</p>
                                 <p>Treatment with locally effective antibiotics.</p>
                                 <p>Duration of treatment: 3 weeks.</p>
                              </td>
                           </tr>
                           <tr>
                              <td rowspan="1" colspan="1">Culture-negative peritonitis</td>
                              <td rowspan="1" colspan="1">
                                 <p>A repeat dialysis effluent analysis after three days of therapy. If effluent analysis results show improvement, we should narrow down the antibiotic therapy spectrum (e.g., replace aminoglycosides with a first-generation cephalosporin or vancomycin).</p>
                                 <p>Duration of treatment: 2 weeks.</p>
                              </td>
                           </tr>
                           <tr>
                              <td rowspan="1" colspan="1">Fungal peritonitis</td>
                              <td rowspan="1" colspan="1">
                                 <p>Immediate catheter removal.</p>
                                 <p>Treatment with a locally effective antimycotic medication.</p>
                                 <p>Duration of treatment: at least 2 weeks.</p>
                              </td>
                           </tr>
                        </tbody>
                     </table>
                  </table-wrap>
                  <xref ref-type="table" rid="en-table2">Table 2</xref> (<xref ref-type="bibr" rid="en-b3">3</xref>,<xref ref-type="bibr" rid="en-b4">4</xref>).</p>
            </sec>
            <sec id="en-s7.3" sec-type="Evaluating treatment outcomes">
               <label>7.3</label>
               <title>Evaluating treatment outcomes</title>
               <p>After commencing the treatment, we regularly monitor patients and assess whether their clinical status is improving. We should expect an improvement of clinical status and partial clarification of the cloudy effluent within 48 hours of starting the treatment, at which point we determine the leukocyte count and the percentage of neutrophils in the effluent. If their number does not drop after three days of treatment, the possibility that the treatment will be effective falls below 64% (<xref ref-type="bibr" rid="en-b11">11</xref>,<xref ref-type="bibr" rid="en-b25">25</xref>). In these cases, it is sensible to switch from intermittent to continuous antibiotic administration. If that is not possible, we should increase the dose and frequency of antibiotic delivery (<xref ref-type="bibr" rid="en-b11">11</xref>).</p>
            </sec>
            <sec id="en-s7.4"
                 sec-type="Indications for catheter removal and replacement">
               <label>7.4</label>
               <title>Indications for catheter removal and replacement</title>
               <p>Sometimes antimicrobial therapy is ineffective in treating peritonitis, so we should consider removing the peritoneal catheter. Early removal after ineffective antimicrobial therapy decreases the mortality and the duration of peritonitis episodes. Indications for removing the peritoneal catheter are:</p>
               <list>
                  <list-item>
                     <label>•</label>
                     <p>refractory peritonitis (the patient does not respond to the antibiotic therapy as expected within 5 days);</p>
                  </list-item>
                  <list-item>
                     <label>•</label>
                     <p>recurrent peritonitis (peritonitis recurring within four weeks);</p>
                  </list-item>
                  <list-item>
                     <label>•</label>
                     <p>fungal or mycobacterial peritonitis;</p>
                  </list-item>
                  <list-item>
                     <label>•</label>
                     <p>peritonitis accompanying other pathological conditions in the abdomen (e.g. abscess, perforation, etc.);</p>
                  </list-item>
                  <list-item>
                     <label>•</label>
                     <p>culture-negative peritonitis with persistently elevated dialysis effluent leukocyte counts.</p>
                  </list-item>
               </list>
               <p>A new catheter may be inserted with recurrent peritonitis, if PD effluent becomes clear with initial therapy. In other cases, the catheter should be removed and a new one should not be inserted immediately, but only after a minimum of 2 weeks of therapy with an antimicrobial pharmaceutical. A new catheter should only be inserted 2–4 weeks after the removal, after complete resolution of peritonitis symptom (<xref ref-type="bibr" rid="en-b4">4</xref>,<xref ref-type="bibr" rid="en-b11">11</xref>,<xref ref-type="bibr" rid="en-b12">12</xref>).</p>
            </sec>
            <sec id="en-s7.5" sec-type="Adjunctive treatments and specifics">
               <label>7.5</label>
               <title>Adjunctive treatments and specifics</title>
               <p>Some patients with PD-related peritonitis could be managed on an outpatient basis. The decision to hospitalize a patient depends on their hemodynamic stability, and the severity of signs and symptoms. If the patient is affected by severe pain, they should be provided with a sufficient amount of analgesics. ISPD recommends systemic antifungal prophylaxis, since fungal infections are hard to treat, and virtually always require catheter removal, and they most frequently occur during antibiotic therapy. For patients with cloudy effluent, the guidelines recommend heparin 500 units/L IP to prevent occlusion of the catheter by fibrin (<xref ref-type="bibr" rid="en-b4">4</xref>).</p>
            </sec>
         </sec>
         <sec id="en-s8" sec-type="Prevention">
            <label>8</label>
            <title>Prevention</title>
            <p>Prevention of peritonitis remains a challenge, and is as important as early diagnosis and timely treatment. Every centre providing PD must regularly monitor and analyse peritonitis rate in patients, and provide adequate prevention measures (<xref ref-type="bibr" rid="en-b3">3</xref>,<xref ref-type="bibr" rid="en-b5">5</xref>,<xref ref-type="bibr" rid="en-b26">26</xref>).</p>
            <p>ISPD’s updated guidelines from 2016 give the following recommendations for preventing peritonitis in PD.</p>
            <p>Dialysis catheter placement. Administering a parenteral prophylactic antibiotics dose prior to peritoneal catheter insertion has been proven to reduce early peritonitis incidence. Based on the conducted studies, the use of cephalosporins, gentamicin and vancomycin is recommended, and local susceptibility of bacteria must be considered when deciding on the antibiotic. At the University Medical Centre Ljubljana (UKC LJ), one 2 g dose of cefazolin 30–60 minutes before the surgical incision is used for antibiotic prophylaxis. Sometimes we prescribe a higher dose (3 g) to overweight patients (<xref ref-type="bibr" rid="en-b27">27</xref>,<xref ref-type="bibr" rid="en-b28">28</xref>). The catheter insertion technique does not affect peritonitis incidence (<xref ref-type="bibr" rid="en-b4">4</xref>,<xref ref-type="bibr" rid="en-b5">5</xref>,<xref ref-type="bibr" rid="en-b18">18</xref>,<xref ref-type="bibr" rid="en-b19">19</xref>,<xref ref-type="bibr" rid="en-b26">26</xref>,<xref ref-type="bibr" rid="en-b29">29</xref>). In the recent years, UKC LJ has only been using laparoscopy for inserting peritoneal dialysis catheters. We placed 22 catheters in 2016, without recording any major early complications (<xref ref-type="bibr" rid="en-b27">27</xref>).</p>
            <p>Catheter design. There are several types and shapes of catheters – straight, curved and swan-neck. They are usually made from silicone, and sometimes from polyurethane. Most commonly used catheters have two Dacron cuffs, which are anchored in the abdominal wall during the insertion to properly fixate the catheter (<xref ref-type="bibr" rid="en-b27">27</xref>). Several studies have compared peritonitis rate for straight and curved catheters, and found no significant difference (<xref ref-type="bibr" rid="en-b4">4</xref>).</p>
            <p>Dialysis method. We use exclusively the double bag system, for which peritonitis rates are about 30% lower compared to other methods (<xref ref-type="bibr" rid="en-b3">3</xref>,<xref ref-type="bibr" rid="en-b4">4</xref>,<xref ref-type="bibr" rid="en-b6">6</xref>,<xref ref-type="bibr" rid="en-b18">18</xref>).</p>
            <p>Training of patients and their family. Experienced dialysis staff must teach the patient and their family how to properly perform the peritoneal dialysis, since the quality of training greatly affects the rate of peritonitis. Unfortunately, there are no evidence-based recommendations clearly specifying when, where and how frequently such training should be provided. It is important that when the patient starts PD, nursing staff with experience in peritoneal dialysis visits them to check for potential mistakes and correct the patient (<xref ref-type="bibr" rid="en-b3">3</xref>-<xref ref-type="bibr" rid="en-b5">5</xref>,<xref ref-type="bibr" rid="en-b26">26</xref>).</p>
            <p>Dialysis Solution. Several studies have examined the effect of different dialysis solutions in use. It is suggested that neutral-pH, low-glucose-degradation-product PD solutions are more biocompatible and lower the occurrence of peritonitis compared to other dialysis solutions. However, confirming these assumptions would require more research, and the currently held opinion is that the type of solution does not affect the peritonitis incidence (<xref ref-type="bibr" rid="en-b4">4</xref>,<xref ref-type="bibr" rid="en-b18">18</xref>,<xref ref-type="bibr" rid="en-b30">30</xref>).</p>
            <p>Catheter exit site care. Daily topical application of antibiotic ointment to the catheter exit site is recommended. Proper hand hygiene is essential when performing the dialysis. Wearing a face mask is not obligatory, it is however recommended and advised (<xref ref-type="bibr" rid="en-b3">3</xref>-<xref ref-type="bibr" rid="en-b5">5</xref>).</p>
            <p>Antibiotic prophylaxis before procedures. Due to the increased peritonitis risk in PD patients after procedures, antibiotic prophylaxis is recommended prior to colonoscopy and invasive gynecologic procedures (<xref ref-type="bibr" rid="en-b4">4</xref>).</p>
         </sec>
         <sec id="en-s9" sec-type="Prognosis">
            <label>9</label>
            <title>Prognosis</title>
            <p>Although mortality rate in PD patients has decreased in the past years, the long-term survival is relatively low (<xref ref-type="bibr" rid="en-b11">11</xref>,<xref ref-type="bibr" rid="en-b15">15</xref>). While the one-year survival rate stands at 86%, the 10-year survival rate is only about 11% (<xref ref-type="bibr" rid="en-b15">15</xref>). There are several contributing factors to the low 10-year survival rate, which depends on the patient characteristics and factors at the dialysis centre (<xref ref-type="bibr" rid="en-b15">15</xref>). It should be noted that the data on long-term survival may be misleading, and require attention when interpreting, since patients are rarely treated with PD for more than 5 years. They frequently switch to another replacement therapy, which analyses often interpret as a failure of PD, and take it into account when estimating long-term survival. In 2013, 12.3% of PD patients died in Slovenia (<xref ref-type="bibr" rid="en-b17">17</xref>).</p>
            <p>Several factors have been known to affect the survival of PD patients. A number of factors, such as age, diabetes and chronic renal failure etiology, are unchangeable and cannot be affected. We should focus on the factors that can be changed and that affect the long-term prognosis. These are primarily the remaining renal function, the preserved integrity and function of the peritoneal membrane, and peritonitis. We recommend prescribing angiotensin-converting-enzyme inhibitors (ACEI) to all patients who tolerate ACEI well, whether they suffer from hypertension or not, since ACEI helps preserve the remaining renal function. The residual renal function is a good prognostic factor, predicting better outcome in PD and hemodialysis patients. One of the studies found that for every 250 ml of residual urine production, the 2-year mortality dropped by about 36% (<xref ref-type="bibr" rid="en-b15">15</xref>). Cardiovascular causes account for most deaths in PD patients (<xref ref-type="bibr" rid="en-b18">18</xref>).</p>
            <p>Peritonitis-related mortality in PD patients has declined significantly in the past decades due to preventive measures. The rate of cured cases of peritonitis remains high and stable, despite the increasing antibiotic resistance of microorganisms. While less than 5% of episodes result in death, peritonitis still remains a major contributing cause of mortality in approximately 16% of deaths. A peritonitis episode increases the risk of death from an infection, associated cardiovascular diseases and the discontinuation of PD. Peritonitis is the most frequent cause for removing the peritoneal catheter, discontinuing PD and switch to long-term hemodialysis (<xref ref-type="bibr" rid="en-b4">4</xref>,<xref ref-type="bibr" rid="en-b6">6</xref>,<xref ref-type="bibr" rid="en-b18">18</xref>).</p>
         </sec>
         <sec id="en-s10" sec-type="Conclusion">
            <label>10</label>
            <title>Conclusion</title>
            <p>Peritonitis is a possible and serious, life-threatening complication accompanying PD, which can severely affect the patient. The time between the onset of peritonitis and the commencement of treatment critically determines the course and prognosis of peritonitis, so immediate action is needed. Peritonitis is treated by eliminating the origin of infection, rinsing the abdominal cavity with a 0.9% NaCl solution, and introducing first empiric and then targeted antimicrobial therapy. Peritonitis is the most frequent cause for removing the peritoneal catheter, discontinuing PD and switch to long-term hemodialysis, so its prevention should be the priority of every dialysis centre. Special emphasis should be put on training the patient and their family, especially after a peritonitis episode, since incorrect manipulation of the peritoneal catheter is a frequent cause of the infection.</p>
         </sec>
      </body>
      <back>
         <ref-list>
            <ref id="en-b1">
               <label>1. </label>
               <mixed-citation publication-type="book-chapter" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Omejc</surname> 
                        <given-names>M</given-names>
                     </string-name>
                  </person-group>. <chapter-title>Kirurgija trebušne votline</chapter-title>. In: <person-group person-group-type="editor">
                     <string-name name-style="western">
                        <surname>Smrkolj</surname> 
                        <given-names>V</given-names>
                     </string-name>, <role>editor</role>
                  </person-group>. <source>Kirurgija. Celje: Grafika Gracer</source>. <year>2014</year>. pp. <fpage>1000</fpage>–<lpage>2</lpage>.<annotation>
                     <p content-type="warning">Could not find a publisher location in this book chapter reference. (Ref. 1 "Omejc, 2014")</p>
                     <p content-type="warning">Could not find a publisher name in this book chapter reference. (Ref. 1 "Omejc, 2014")</p>
                  </annotation>
               </mixed-citation>
            </ref>
            <ref id="en-b2">
               <label>2. </label>
               <mixed-citation publication-type="book" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Townsend</surname> 
                        <given-names>C</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Beauchamp</surname> 
                        <given-names>RD</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Evers</surname> 
                        <given-names>BM</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Mattox</surname> 
                        <given-names>K</given-names>
                     </string-name>
                  </person-group>. <source>Sabiston Textbook of Surgery: the Biological Basis of Modern Surgical Practice</source>. <publisher-loc>Amsterdam</publisher-loc>: <publisher-name>Elsevier</publisher-name>; <year>2017</year>.</mixed-citation>
            </ref>
            <ref id="en-b3">
               <label>3.	</label>
               <mixed-citation publication-type="book" specific-use="unparsed">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Košnik</surname> 
                        <given-names>M</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Mrevlje</surname> 
                        <given-names>F</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Štajer</surname> 
                        <given-names>D</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Černelč</surname> 
                        <given-names>P</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Koželj</surname> 
                        <given-names>M</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Andoljšek</surname> 
                        <given-names>D</given-names>
                     </string-name>, <etal>et al.</etal>
                  </person-group> 
                  <source>Interna medicina.</source> Ljubljana: Littera picta: Slovensko medicinsko društvo; <year>2011</year>. p. 1133-1137.<annotation>
                     <p content-type="warning">Edifix Bibliographic Reference Processing failed to fully style this reference. Please check the copyediting. (Ref. 3 "Košnik, Mrevlje, Štajer, Černelč, Koželj, Andoljšek, et al., 2011")</p>
                  </annotation>
               </mixed-citation>
            </ref>
            <ref id="en-b4">
               <label>4.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Li</surname> 
                        <given-names>PK</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Szeto</surname> 
                        <given-names>CC</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Piraino</surname> 
                        <given-names>B</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>de Arteaga</surname> 
                        <given-names>J</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Fan</surname> 
                        <given-names>S</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Figueiredo</surname> 
                        <given-names>AE</given-names>
                     </string-name>, <etal>et al.</etal>
                  </person-group> 
                  <article-title>ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment</article-title>. <source>Perit Dial Int</source>. <year>2016</year> 
                  <month>Sep</month>;<volume>36</volume>(<issue>5</issue>):<fpage>481</fpage>–<lpage>508</lpage>. <pub-id pub-id-type="doi">10.3747/pdi.2016.00078</pub-id>
                  <pub-id pub-id-type="pmid">27282851</pub-id>
                  <issn>0896-8608</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b5">
               <label>5.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Segal</surname> 
                        <given-names>JH</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Messana</surname> 
                        <given-names>JM</given-names>
                     </string-name>
                  </person-group>. <article-title>Prevention of peritonitis in peritoneal dialysis</article-title>. <source>Semin Dial</source>. <year>2013</year> 
                  <month>Jul-Aug</month>;<volume>26</volume>(<issue>4</issue>):<fpage>494</fpage>–<lpage>502</lpage>. <pub-id pub-id-type="doi">10.1111/sdi.12114</pub-id>
                  <pub-id pub-id-type="pmid">23859192</pub-id>
                  <issn>0894-0959</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b6">
               <label>6.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Szeto</surname> 
                        <given-names>CC</given-names>
                     </string-name>
                  </person-group>. <article-title>Peritonitis rates of the past thirty years: from improvement to stagnation</article-title>. <source>Perit Dial Int</source>. <year>2014</year> 
                  <month>Mar-Apr</month>;<volume>34</volume>(<issue>2</issue>):<fpage>151</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.3747/pdi.2014.00007</pub-id>
                  <pub-id pub-id-type="pmid">24676740</pub-id>
                  <issn>0896-8608</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b7">
               <label>7.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Khilji</surname> 
                        <given-names>MF</given-names>
                     </string-name>
                  </person-group>. <article-title>Primary Peritonitis-A Forgotten Entity</article-title>. <source>European J Pediatr Surg Rep</source>. <year>2015</year> 
                  <month>Jun</month>;<volume>3</volume>(<issue>1</issue>):<fpage>27</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">26171311</pub-id>
                  <issn>2194-7619</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b8">
               <label>8. </label>
               <mixed-citation publication-type="book-chapter" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Holzheimer</surname> 
                        <given-names>RG</given-names>
                     </string-name>
                  </person-group>. <chapter-title>Management of secondary peritonitis</chapter-title>. In: <person-group person-group-type="editor">
                     <string-name name-style="western">
                        <surname>Holzheimer</surname> 
                        <given-names>RG</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Mannick</surname> 
                        <given-names>JA</given-names>
                     </string-name>, <role>editors</role>
                  </person-group>. <source>Surgical Treatment: Evidence-Based and Problem-Oriented</source>. <publisher-loc>Munich</publisher-loc>: <publisher-name>Zuckschwerdt</publisher-name>; <year>2001</year>.</mixed-citation>
            </ref>
            <ref id="en-b9">
               <label>9.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Mishra</surname> 
                        <given-names>SP</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Tiwary</surname> 
                        <given-names>SK</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Mishra</surname> 
                        <given-names>M</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Gupta</surname> 
                        <given-names>SK</given-names>
                     </string-name>
                  </person-group>. <article-title>An introduction of Tertiary Peritonitis</article-title>. <source>J Emerg Trauma Shock</source>. <year>2014</year> 
                  <month>Apr</month>;<volume>7</volume>(<issue>2</issue>):<fpage>121</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.4103/0974-2700.130883</pub-id>
                  <pub-id pub-id-type="pmid">24812458</pub-id>
                  <issn>0974-2700</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b10">
               <label>10.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Walker</surname> 
                        <given-names>A</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Bannister</surname> 
                        <given-names>K</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>George</surname> 
                        <given-names>C</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Mudge</surname> 
                        <given-names>D</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Yehia</surname> 
                        <given-names>M</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Lonergan</surname> 
                        <given-names>M</given-names>
                     </string-name>, <etal>et al.</etal>
                  </person-group> 
                  <article-title>KHA-CARI Guideline: peritonitis treatment and prophylaxis</article-title>. <source>Nephrology (Carlton)</source>. <year>2014</year> 
                  <month>Feb</month>;<volume>19</volume>(<issue>2</issue>):<fpage>69</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1111/nep.12152</pub-id>
                  <pub-id pub-id-type="pmid">23944845</pub-id>
                  <issn>1320-5358</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b11">
               <label>11.	</label>
               <mixed-citation publication-type="web-page" specific-use="unparsed">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Burkart</surname> 
                        <given-names>MD</given-names>
                     </string-name>
                  </person-group>. <article-title>Microbiology and therapy of peritonitis in peritoneal dialysis.</article-title> Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc [cited 2018 May 15]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.uptodate.com">http://www.uptodate.com</ext-link>
               </mixed-citation>
            </ref>
            <ref id="en-b12">
               <label>12.	</label>
               <mixed-citation publication-type="web-page" specific-use="unparsed">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Burkart</surname> 
                        <given-names>MD</given-names>
                     </string-name>
                  </person-group>. <article-title>Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis.</article-title> Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <ext-link ext-link-type="uri" xlink:href="http://www.uptodate.com">http://www.uptodate.com</ext-link> (dostopno 15. maja <year>2018</year>).<annotation>
                     <p content-type="warning">Reference 12 "Burkart, 2018" is similar to reference 11 and may be a duplicate. Please compare these references carefully.</p>
                  </annotation>
               </mixed-citation>
            </ref>
            <ref id="en-b13">
               <label>13.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Montravers</surname> 
                        <given-names>P</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Blot</surname> 
                        <given-names>S</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Dimopoulos</surname> 
                        <given-names>G</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Eckmann</surname> 
                        <given-names>C</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Eggimann</surname> 
                        <given-names>P</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Guirao</surname> 
                        <given-names>X</given-names>
                     </string-name>, <etal>et al.</etal>
                  </person-group> 
                  <article-title>Therapeutic management of peritonitis: a comprehensive guide for intensivists</article-title>. <source>Intensive Care Med</source>. <year>2016</year> 
                  <month>Aug</month>;<volume>42</volume>(<issue>8</issue>):<fpage>1234</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1007/s00134-016-4307-6</pub-id>
                  <pub-id pub-id-type="pmid">26984317</pub-id>
                  <issn>0342-4642</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b14">
               <label>14.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Cho</surname> 
                        <given-names>Y</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Johnson</surname> 
                        <given-names>DW</given-names>
                     </string-name>
                  </person-group>. <article-title>Peritoneal dialysis-related peritonitis: towards improving evidence, practices, and outcomes</article-title>. <source>Am J Kidney Dis</source>. <year>2014</year> 
                  <month>Aug</month>;<volume>64</volume>(<issue>2</issue>):<fpage>278</fpage>–<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1053/j.ajkd.2014.02.025</pub-id>
                  <pub-id pub-id-type="pmid">24751170</pub-id>
                  <issn>0272-6386</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b15">
               <label>15.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Kendrick</surname> 
                        <given-names>J</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Teitelbaum</surname> 
                        <given-names>I</given-names>
                     </string-name>
                  </person-group>. <article-title>Strategies for improving long-term survival in peritoneal dialysis patients</article-title>. <source>Clin J Am Soc Nephrol</source>. <year>2010</year> 
                  <month>Jun</month>;<volume>5</volume>(<issue>6</issue>):<fpage>1123</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.2215/CJN.04300709</pub-id>
                  <pub-id pub-id-type="pmid">20430945</pub-id>
                  <issn>1555-9041</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b16">
               <label>16.	</label>
               <mixed-citation publication-type="book-chapter" specific-use="unparsed">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Kovač</surname> 
                        <given-names>D</given-names>
                     </string-name>
                  </person-group>. <chapter-title>Kako povečati program peritonealne dialize v Sloveniji.</chapter-title> In: 30-letnica kontinuirane peritonealne dialize v Sloveniji; 20. in 21. november 2014; Hotel Mons, Slovensko nefrološko društvo, Ljubljana, Slovenija. Ljubljana: UKC, KO za nefrologijo; <year>2014</year>.<annotation>
                     <p content-type="warning">Edifix Bibliographic Reference Processing failed to fully style this reference. Please check the copyediting. (Ref. 16 "Kovač, 2014")</p>
                  </annotation>
               </mixed-citation>
            </ref>
            <ref id="en-b17">
               <label>17.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Buturović-Ponikvar</surname> 
                        <given-names>J</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Gubenšek</surname> 
                        <given-names>J</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Arnol</surname> 
                        <given-names>M</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Adamlje</surname> 
                        <given-names>T</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Ceglar</surname> 
                        <given-names>Z</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Damevska</surname> 
                        <given-names>G</given-names>
                     </string-name>, <etal>et al.</etal>
                  </person-group> 
                  <article-title>Renal Replacement Therapy in Slovenia: Excerpts From 2013 Data</article-title>. <source>Ther Apher Dial</source>. <year>2016</year> 
                  <month>Jun</month>;<volume>20</volume>(<issue>3</issue>):<fpage>223</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/1744-9987.12427</pub-id>
                  <pub-id pub-id-type="pmid">27312905</pub-id>
                  <issn>1744-9979</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b18">
               <label>18.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Mehrotra</surname> 
                        <given-names>R</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Devuyst</surname> 
                        <given-names>O</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Davies</surname> 
                        <given-names>SJ</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Johnson</surname> 
                        <given-names>DW</given-names>
                     </string-name>
                  </person-group>. <article-title>The Current State of Peritoneal Dialysis</article-title>. <source>J Am Soc Nephrol</source>. <year>2016</year> 
                  <month>Nov</month>;<volume>27</volume>(<issue>11</issue>):<fpage>3238</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1681/ASN.2016010112</pub-id>
                  <pub-id pub-id-type="pmid">27339663</pub-id>
                  <issn>1046-6673</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b19">
               <label>19.	</label>
               <mixed-citation publication-type="book" specific-use="unparsed">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Tomažič</surname> 
                        <given-names>J</given-names>
                     </string-name>
                  </person-group>. in Strle F. s sodelavci. Infekcijske bolezni. Ljubljana: Slovensko zdravniško društvo, Združenje za infektologijo; <year>2014/2015</year>. p. 375<annotation>
                     <p content-type="warning">Edifix Bibliographic Reference Processing failed to fully style this reference. Please check the copyediting. (Ref. 19 "Tomažič, 2014/2015")</p>
                  </annotation>
               </mixed-citation>
            </ref>
            <ref id="en-b20">
               <label>20.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Mlinšek</surname> 
                        <given-names>D</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Savicki</surname> 
                        <given-names>B</given-names>
                     </string-name>
                  </person-group>. <article-title>Postopki pri zdravljenju peritonitisa kot zaplet kontinuirane peritonealne dialize. Ljubljana</article-title>. <source>Obzor Zdr N.</source> 
                  <year>1994</year>;<volume>28</volume>:<fpage>109</fpage>–<lpage>11</lpage>.<annotation>
                     <p content-type="warning">Edifix does not recognize the journal "Obzor Zdr N.". If this is a valid journal title, please send this reference to journals@inera.com for addition to our journal database. (Ref. 20 "Mlinšek, Savicki, 1994")</p>
                     <p content-type="warning">Edifix has not found an issue number in the journal reference. Please check the volume/issue information. (Ref. 20 "Mlinšek, Savicki, 1994")</p>
                  </annotation>
               </mixed-citation>
            </ref>
            <ref id="en-b21">
               <label>21.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Akoh</surname> 
                        <given-names>JA</given-names>
                     </string-name>
                  </person-group>. <article-title>Peritoneal dialysis associated infections: an update on diagnosis and management</article-title>. <source>World J Nephrol</source>. <year>2012</year> 
                  <month>Aug</month>;<volume>1</volume>(<issue>4</issue>):<fpage>106</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.5527/wjn.v1.i4.106</pub-id>
                  <pub-id pub-id-type="pmid">24175248</pub-id>
                  <issn>2220-6124</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b22">
               <label>22.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Okamoto</surname> 
                        <given-names>T</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Ikenoue</surname> 
                        <given-names>T</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Matsui</surname> 
                        <given-names>K</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Miyazaki</surname> 
                        <given-names>M</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Tsuzuku</surname> 
                        <given-names>Y</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Nishizawa</surname> 
                        <given-names>Y</given-names>
                     </string-name>, <etal>et al.</etal>
                  </person-group> 
                  <article-title>Free air on CT and the risk of peritonitis in peritoneal dialysis patients: a retrospective study</article-title>. <source>Ren Fail</source>. <year>2014</year> 
                  <month>Nov</month>;<volume>36</volume>(<issue>10</issue>):<fpage>1492</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.3109/0886022X.2014.958953</pub-id>
                  <pub-id pub-id-type="pmid">25211321</pub-id>
                  <issn>0886-022X</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b23">
               <label>23.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Temiz</surname> 
                        <given-names>G</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Sahin</surname> 
                        <given-names>G</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Mukerrem</surname> 
                        <given-names>G</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Ozkurt</surname> 
                        <given-names>S</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Degirmenci</surname> 
                        <given-names>NA</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Yalcin</surname> 
                        <given-names>AU</given-names>
                     </string-name>
                  </person-group>. <article-title>Ultrasonographic evaluation of peritoneal membrane thickness and comparison with the effectiveness and duration of CAPD</article-title>. <source>Int Urol Nephrol</source>. <year>2013</year> 
                  <month>Dec</month>;<volume>45</volume>(<issue>6</issue>):<fpage>1761</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1007/s11255-013-0504-1</pub-id>
                  <pub-id pub-id-type="pmid">23884729</pub-id>
                  <issn>0301-1623</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b24">
               <label>24.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Barretti</surname> 
                        <given-names>P</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Doles</surname> 
                        <given-names>JV</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Pinotti</surname> 
                        <given-names>DG</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>El Dib</surname> 
                        <given-names>R</given-names>
                     </string-name>
                  </person-group>. <article-title>Efficacy of antibiotic therapy for peritoneal dialysis-associated peritonitis: a proportional meta-analysis</article-title>. <source>BMC Infect Dis</source>. <year>2014</year> 
                  <month>Aug</month>;<volume>14</volume>(<issue>1</issue>):<fpage>445</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2334-14-445</pub-id>
                  <pub-id pub-id-type="pmid">25135487</pub-id>
                  <issn>1471-2334</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b25">
               <label>25.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Chow</surname> 
                        <given-names>KM</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Szeto</surname> 
                        <given-names>CC</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Cheung</surname> 
                        <given-names>KK</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Leung</surname> 
                        <given-names>CB</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Wong</surname> 
                        <given-names>SS</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Law</surname> 
                        <given-names>MC</given-names>
                     </string-name>, <etal>et al.</etal>
                  </person-group> 
                  <article-title>Predictive value of dialysate cell counts in peritonitis complicating peritoneal dialysis</article-title>. <source>Clin J Am Soc Nephrol</source>. <year>2006</year> 
                  <month>Jul</month>;<volume>1</volume>(<issue>4</issue>):<fpage>768</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.2215/CJN.01010306</pub-id>
                  <pub-id pub-id-type="pmid">17699285</pub-id>
                  <issn>1555-9041</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b26">
               <label>26.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Bender</surname> 
                        <given-names>FH</given-names>
                     </string-name>
                  </person-group>. <article-title>Avoiding harm in peritoneal dialysis patients</article-title>. <source>Adv Chronic Kidney Dis</source>. <year>2012</year> 
                  <month>May</month>;<volume>19</volume>(<issue>3</issue>):<fpage>171</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1053/j.ackd.2012.04.002</pub-id>
                  <pub-id pub-id-type="pmid">22578677</pub-id>
                  <issn>1548-5595</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b27">
               <label>27.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Janež</surname> 
                        <given-names>J</given-names>
                     </string-name>
                  </person-group>. <article-title>Laparoskopska vstavitev katetra za peritonealno dializo</article-title>. <source>Med Razgl</source>. <year>2017</year>;<volume>56</volume>(<issue>4</issue>):<fpage>517</fpage>–<lpage>24</lpage>.<issn>0025-8121</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b28">
               <label>28.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Pintar</surname> 
                        <given-names>T</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Trotovšek</surname> 
                        <given-names>B</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Beović</surname> 
                        <given-names>B</given-names>
                     </string-name>
                  </person-group>. <article-title>Smernice za profilaktično uporabo antibiotikov v abdominalni kirurgiji za odrasle</article-title>. <source>Zdrav Vestn</source>. <year>2014</year>;<volume>83</volume>:<fpage>651</fpage>–<lpage>60</lpage>.<issn>0350-0063</issn>
                  <annotation>
                     <p content-type="warning">Edifix has not found an issue number in the journal reference. Please check the volume/issue information. (Ref. 28 "Pintar, Trotovšek, Beović, 2014")</p>
                  </annotation>
               </mixed-citation>
            </ref>
            <ref id="en-b29">
               <label>29.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Gadallah</surname> 
                        <given-names>MF</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Ramdeen</surname> 
                        <given-names>G</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Mignone</surname> 
                        <given-names>J</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Patel</surname> 
                        <given-names>D</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Mitchell</surname> 
                        <given-names>L</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Tatro</surname> 
                        <given-names>S</given-names>
                     </string-name>
                  </person-group>. <article-title>Role of preoperative antibiotic prophylaxis in preventing postoperative peritonitis in newly placed peritoneal dialysis catheters</article-title>. <source>Am J Kidney Dis</source>. <year>2000</year> 
                  <month>Nov</month>;<volume>36</volume>(<issue>5</issue>):<fpage>1014</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1053/ajkd.2000.19104</pub-id>
                  <pub-id pub-id-type="pmid">11054359</pub-id>
                  <issn>0272-6386</issn>
               </mixed-citation>
            </ref>
            <ref id="en-b30">
               <label>30.	</label>
               <mixed-citation publication-type="journal" specific-use="restruct">
                  <person-group person-group-type="author">
                     <string-name name-style="western">
                        <surname>Velloso</surname> 
                        <given-names>MS</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Otoni</surname> 
                        <given-names>A</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>de Paula Sabino</surname> 
                        <given-names>A</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>de Castro</surname> 
                        <given-names>WV</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Pinto</surname> 
                        <given-names>SW</given-names>
                     </string-name>, <string-name name-style="western">
                        <surname>Marinho</surname> 
                        <given-names>MA</given-names>
                     </string-name>, <etal>et al.</etal>
                  </person-group> 
                  <article-title>Peritoneal dialysis and inflammation</article-title>. <source>Clin Chim Acta</source>. <year>2014</year> 
                  <month>Mar</month>;<volume>430</volume>:<fpage>109</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.cca.2013.12.003</pub-id>
                  <pub-id pub-id-type="pmid">24333488</pub-id>
                  <issn>0009-8981</issn>
                  <annotation>
                     <p content-type="warning">Edifix has not found an issue number in the journal reference. Please check the volume/issue information. (Ref. 30 "Velloso, Otoni, 2014")</p>
                  </annotation>
               </mixed-citation>
            </ref>
         </ref-list>
      </back>
   </sub-article>
</article>
